

New enolate-carbodiimide rearrangement in concise synthesis of 6-amino-2,3-dihydro-4-pyridinones from homoallylamines.

Kuznetsov N. Yu.^{[a]*}, Tikhov R. M.^[a], Godovikov I. A.^{[a]†}, Khrustalev V. N.^{[a][b]‡}, Bubnov Yu. N.^{[a][c]*}

^[a] *A.N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Vavilov 28, 119991, Moscow, Russian Federation*

^[b] *Department of Inorganic Chemistry, Peoples' Friendship University of Russia, Miklukho-Maklay St., 6, Moscow 117198, Russian Federation*

^[c] *N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky pr. 47, 119991 Moscow, Russia*

* nkuznff@ineos.ac.ru

Supporting Information

Table of Contents:

Experimental procedures	S2-S21
Copies of ¹ H/ ¹³ C NMR spectra	S22-S158
Copies of Chiral HPLC chromatograms.....	S159-S163

Procedures for synthesis of the starting amines.

3-Butenylamine hydrochloride (6). Potassium phthalimid (29.4 g, 0.158 mol), 4-bromo-1-buten (17.0 g, 0.126 mol), TBAB (2.0 g, 6.2 mmol) were mixed in MeCN (200 ml) and resulted suspension was heated under reflux for 5 h, then cooled to ambient temperature, filtered to remove of excess of phthalimid and filtrate was evaporated under reduced pressure. The residue was dissolved in Et₂O (100 ml) and washed with brine twice. The organic phase was dried over K₂CO₃ and evaporated to give *N*-(3-butenyl)phthalimide (24.4 g, 96%) as white solid. It was redissolved in EtOH (150 ml) and treated with hydrazine hydrate (7.8 g, 0.156 mol). The mixture was heated under reflux for 1h, during which time phthalimid is precipitated, then 6N HCl (67 ml, 0.4 mol) was added and the mixture was refluxed for another hour. Finally the reaction mixture was cooled, filtered and filtrate was evaporated. To the residue excess of NaOH 5M was added and 3-butenylamine formed was extracted with Et₂O (30 ml x 3). The dried (over KOH) ethereal extracts were transferred to a flask and acidified with HCl 4M in dioxane (30 ml, 0.12 mol) upon cooling by ice-water bath. Precipitated hydrochloride was filtered, washed with dry Et₂O and dried in vacuum that afford **6** (11.3 g, 88%), m.p. 171-173 °C (EtOH/Et₂O). ¹H NMR (400 MHz, DMSO-D₆) (δ, ppm): 8.26 (br.s, 3H, NH₃⁺); 5.83 (ddt, *J* = 6.6, 10.2, 17.3 Hz, 1H, CH=); 5.19-5.10 (m, 2H, CH₂=); 2.88-2.81 (m, 2H, CH₂NH₃⁺), 2.42-2.35 (br.m, 2H, CH₂CH=).

(*R,S*)-*N*-[(1*S*)-1-phenyl-3-butenyl]-2-methyl-2-propanesulfinamide (10) and (*S*)-1-phenyl-3-buten-1-amine ((*S*)-7)

To zinc powder (0.98 g, 15 mmol) in THF (15 ml) preactivated with TMSCl (6 drops, 10 min) allylbromide (1.81 g, 1.30 ml, 15 mmol) was added dropwise with stirring. After the formation of allylzinc bromide was completed, TMEDA (1.86 g, 2.41 ml, 16 mmol) was added. Then the reaction mixture was cooled to 0 °C and imine **9** (2,09 g, 10 mmol) in THF (2 ml) was added dropwise, stirring was continued for 20 min and the reaction was quenched with NH₄Cl(sat.) (80 ml) with vigorous stirring for 30 min. The product was extracted with Et₂O/*n*-C₆H₁₄ (1:1, 40 ml x 3), the combined extracts were washed with brine, dried over MgSO₄, filtered and evaporated under reduced pressure that affords crude **10** (2.12 g, 85%, *de* 75%) as a mixture of *RS* and *RR*-isomers according to ¹H NMR. ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 7.37-7.27 (m, 5H, Ph); 5.80-5.69 (m, 1H, CH=, *RS*); 5.68-5.57 (m, 0.15H, CH=, *RR*); 5.22-5.17 (m, 2H, CH₂=, *RS*); 5.07-5.02 (m, 0.30H, CH₂=, *RR*); 4.48 (ddd, *J* = 2.2, 5.5, 8.2 Hz, 1.15H, *RS* and *RR*); 3.69 (br. s, 1H, NH, *RS*); 3.53 (br. d, *J* = 3.5 Hz, 0.15H, NH, *RR*); 2.79-2.72 (m, 0.15H, CH_AH_B, *RR*); 2.61 (dt, *J* = 1.4, 5.8, 14.0 Hz, 1.15H, CH_AH_B *RS* and CH_AH_B *RR*); 2.61 (dt, *J* = 8.3, 14.0 Hz, 1H, CH_AH_B *RS*); 1.24 (s, 1.35H, *t*Bu, *RR*); 1.21 (s, 9H, *t*Bu, *RS*). Crude sulfinamide **10** was

dissolved in MeOH (10 ml) followed by addition of 4M HCl in dioxane (9.0 ml, 36 mmol) and the resulting solution was left for a night. The volatiles were removed under reduced pressure, diethyl ether was added (30 ml) and the solid was filtered off to give after drying hydrochloride (**S**)-7 (1.53 g, 95%). ¹H NMR (400 MHz, DMSO-D₆) (δ, ppm): 8.68 (br.s, 3H, NH₃); 7.44-7.43 (m, 2H, Ph); 7.33-7.24 (m, 3H, Ph); 5.55-5.45 (m, 1H, CH=); 4.96-4.89 (m, 2H, CH₂=); 4.19 (dd, *J* = 5.4, 8.9 Hz, 1H, CHPh); 2.72 (dt, *J* = 6.4, 14.0 Hz, 1H, CH_AH_B); 2.53 (dt, *J* = 8.6, 13.7 Hz, 1H, CH_AH_B). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 137.92; 133.31; 129.03 2C; 128.90; 128.11 2C; 119.27; 54.41; 39.01.

Preparation of *N*-Boc derivative (S**)-7 and attempt of its resolution.** Et₃N (2.73 g, 3.75 ml, 27 mmol), Boc-anhydride (3.92 g, 18 mmol), MeCN (7 ml) and THF (5 ml) were added to the (**S**)-7 and the mixture was refluxed with stirring for 2 h. Then all volatiles were removed. The mixture was diluted with Et₂O:*n*-C₆H₁₄ (1:1), the salt was filtered, washed with *n*-hexane. Evaporation of the clear solution gave rise to ***N*-Boc-7** which was crystallized from *n*-hexane several times. The enantiomeric purity was evaluated by measurement of optical rotation of the solution of ***N*-Boc-7**, that reached 84% *ee*, [α]_D²⁵ – 40.5 (c = 1, CHCl₃) {ref.ⁱⁱ optical rotation of the *S*-isomer [α]_D²⁵ –48.4 (c = 1, CHCl₃)}. All the amount of ***N*-Boc-7** was treated with 4M HCl in dioxane to convert it back to hydrochloride (**S**)-7.

***N*-(1-Allyl-1-phenyl-3-butenyl)-*N*-(4-methoxybenzyl)amine (**23**).**

Amine **8** (1.87 g, 10 mmol), *p*-anisaldehyde (1.47 g, 10.8 mmol), AcOH (0.6 g, 10 mmol) were dissolved in DCM (20 ml) and to the solution NaBH(OAc)₃ (3.60 g, 17 mmol) was added with stirring. The mixture was left for a night with stirring at ambient temperature after then quenched by the addition of 5M NaOH (24 ml, 0.12 mol) with stirring for 1h. Organic phase was separated, washed with water and dried with K₂CO₃. Evaporation furnished crude amine **23**, which was purified by FC on silica in *n*-C₆H₁₄:EtOAc, 10:1 that gave pure **23** (2.62 g, 85%) as oil. R_f = 0.58 (*n*-C₆H₁₄:EtOAc, 6:1). ¹H NMR (300 MHz, CDCl₃) (δ, ppm): 7.61-7.58 (m, 2H, Ph); 7.47-7.42 (m, 2H, Ph); 7.34-7.30 (m, 1H, Ph); 7.32 (d, *J* = 8.5 Hz, 2H, Ar); 6.94 (d, *J* = 8.6 Hz, 2H, Ar); 5.80-5.66 (m, 2H, 2CH=); 5.20-5.14 (m, 2H, 2CH₂=); 3.87 (s, 3H, OMe); 3.52 (s, 2H, CH₂Ar); 2.70 (d, *J* = 7.0 Hz, 4H, 2CH₂); 1.62 (br.s, 1H, NH). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 158.50; 145.07; 133.90 2C; 133.15; 129.27 2C; 128.03 2C; 126.71 2C; 126.35; 118.02 2C; 113.69 2C; 60.41; 55.21; 45.53; 41.87 2C. C₂₁H₂₅NO (307.4): calcd. C 82.04, H 8.20, N 4.56; found C 81.98, H 8.25, N 4.67.

1,1-Dimethyl-3-butenylamine (28**).**

To a solution of acetone (3.19 g, 4.04 ml, 55 mmol) in saturated NH₃ solution in MeOH (130 ml) dibutyl ether of allylboronic acid (17.4 g, 88 mmol) in MeOH (30 ml) was added and the solution was left for

one day at 25 °C. Then the reaction mixture was distilled on Vigreux column to remove major part of MeOH and NH₃ until temperature of vapors exceeds 65 °C. The distillation residue was cooled and treated with 6N HCl until pH 1. All volatiles were removed on rotavapor, residue was dissolved in water (10 ml) and extracted with DCM (10 ml x 5) then aqueous phase was basified with NaOH 20% and extracted with *n*-pentane (15 ml x 4), combined extracts were dried over KOH and distilled at atmospheric pressure gathering the fraction boiling at 110-112 °C that furnished amine **28** (3.8 g, 69.8%). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 5.87-5.74 (m, 1H), 5.09-5.03 (m, 2H), 2.07 (d, *J* = 7.6 Hz, 2H), 1.47 (br.s, 2H, NH₂), 1.06 (s, 6H, 2Me). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 134.68, 117.98, 49.35, 49.29, 30.07 2C.

General procedure of synthesis of ureas 11a-d, 16a-d, 20a-c, 16A, 29a,b.

To the hydrochloride homoallylamine **6** (0.86 g, 8.0 mmol) solution in CHCl₃ (15 ml) (or DCM for free amines **7**, **8**, **7A**, **28** and without Et₃N addition) was added corresponding isocyanate (8.0 mmol) and Et₃N (1.0 g, 1.39 ml, 10.0 mmol) dropwise with stirring. The mixture was stirred at ambient temperature for 30 min to ensure completion of the reaction. The progress of the reaction was monitored by TLC. After then the mixture was washed consequently with 0.6N HCl and water. Organic phase was dried with Na₂SO₄ and evaporated to dryness. The residue was recrystallized or purified by FC for elemental analysis.

2-Methoxyethyl *N*-[(3-butenylamino)carbonyl]carbamate (11a).

After FC (*n*-C₆H₁₄/EtOAc, 2:1) yield: 92%, as white crystals, m.p. 48-49 °C. R_f 0.32 (*n*-C₆H₁₄/EtOAc, 2:1). ¹H NMR (300 MHz, CDCl₃) (δ, ppm): 8.59 (s, 1H, NH); 7.80 (s, 1H, NH); 5.80-5.67 (m, 1H, CH=); 5.10-5.02 (m, 2H, CH₂=); 4.25-4.22 (m, 2H, CH₂OC=O); 3.58-3.55 (m, 2H, MeOCH₂); 3.34 (s, 3H, Me); 3.33-3.28 (m, 2H, CH₂N); 2.29-2.22 (m, 2H, CH₂CH=). ¹³C NMR (75 MHz, CDCl₃) (δ, ppm): 154.25; 153.35; 134.89; 117.03; 70.00; 64.76; 58.86; 38.85; 33.59. C₉H₁₆N₂O₄ (216.2): calcd. C 49.99, H 7.46, N 12.96; found C 49.97, H 7.41, N 13.04.

Benzyl *N*-[(3-butenylamino)carbonyl]carbamate (11b).

After FC (*n*-C₆H₁₄/EtOAc, 3:1) yield: 93%, as colourless solid, m.p. 87-88 °C. R_f 0.46 (*n*-C₆H₁₄/EtOAc, 2:1) ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 8.14 (br.s, 1H, NH); 7.82 (br.s, 1H, NH); 7.44-7.29 (m, 5H, Ph); 5.79 (dtt, *J* = 6.8, 10.1, 17.0 Hz, 1H, CH=); 5.17 (s, 2H, CH₂O); 5.16-5.05 (m, 2H, CH₂=); 3.37 (dd, *J* = 6.6, 12.7 Hz, 2H, CH₂N); 2.30 (dd, *J* = 6.8, 13.6 Hz, 2H, CH₂CH=). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 154.12; 153.16; 135.07; 134.98; 128.60(2C); 128.56; 128.01(2C); 117.20; 67.54; 39.07; 33.79. C₁₃H₁₆N₂O₃ (248.3): calcd. C 62.89, H 6.50, N 11.28; found C 62.92, H 6.64, N 11.12.

4-Methylphenylsulfonyl-*N*-(3-butenylamino)carbamate (11c).

Yield: 98%, as white solid, m.p. 108-109 °C. R_f 0.62 (*n*-C₆H₁₄/EtOAc, 1:1). ¹H NMR (300 MHz, CDCl₃) (δ, ppm): 9.34 (br. s, 1H, NHSO₂); 7.83 (d, J = 8.0 Hz, 2H, Ar); 7.35 (d, J = 8.0 Hz, 2H, Ar); 6.63 (br.t, J = 5.4 Hz, 1H, NHCH₂); 5.82-5.69 (m, 1H, CH=); 5.13-5.09 (m, 2H, CH₂=); 3.34 (q, J = 6.2 Hz, 2H, CH₂N); 2.48 (s, 3H, Me); 2.28 (dd, J = 6.4, 13.0 Hz, 2H, CH₂CH=). ¹³C NMR (75 MHz, CDCl₃) (δ, ppm): 152.11; 144.58; 136.62; 134.68; 129.74 2C; 126.99 2C; 117.44; 39.29; 33.55; 21.55. C₁₂H₁₆N₂O₃S (268.3): calcd. C 53.71, H 6.01, N 10.44; found C 53.68, H 6.06, N 10.42.

***N*-(3-Butenyl)-*N'*-(2-iodophenyl)urea (11d).**

Yield: 92%, as white solid, m.p. 121-122 °C. R_f 0.45 (*n*-C₆H₁₄/EtOAc, 1:1) ¹H NMR (600 MHz, CDCl₃) (δ, ppm): 7.86 (d, J = 7.8 Hz, 1H, Ar, C(6)H); 7.76 (d, J = 7.7 Hz, 1H, Ar, C(3)H); 7.29 (t, J = 7.8 Hz, 1H, Ar, C(5)H); 7.29 (t, J = 7.7 Hz, 1H, Ar, C(4)H); 6.73 (s, 1H, NHAr); 5.81-5.74 (m, 1H, CH=); 5.38 (s, 1H, NHCH₂); 5.12-5.07 (m, 2H, CH₂=); 3.34 (t, J = 6.4 Hz, 2H, CH₂N); 2.30 (dt, J = 6.4, 6.9 Hz, 2H, CH₂CH=). ¹³C NMR (150 MHz, CDCl₃) (δ, ppm): 155.27; 139.35; 138.95; 135.23; 129.08; 125.25; 122.93; 117.22; 91.64; 39.54; 34.15. C₁₁H₁₃N₂OI (316.1): calcd. C 41.69, H 4.14, N 8.86; found C 41.83, H 4.10, N 8.88.

***N*-(3-Butenyl)-*N'*-methylurea (11f).**

Yield: 91%, as white powder, m.p. 61-62 °C. R_f 0.29 (EtOAc). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 5.75 (ddt, J = 6.7, 10.2, 17.2 Hz, 1H, CH=); 5.17 (br.s, 2H, 2NH); 5.09-5.02 (m, 2H, CH₂=); 3.22 (dd, J = 6.7, 7.0 Hz, 2H, CH₂N); 2.73 (s, 3H, Me); 2.23 (dt, J = 6.7, 7.0 Hz, 2H, CH₂CH=). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 159.45; 135.48; 116.85; 39.49; 34.44; 26.98. C₆H₁₂N₂O (128.2): calcd. C 56.22, H 9.44, N 21.86; found C 56.33, H 9.37, N 22.01.

***N*-(3-butenyl)-*N'*-(*tert*-butyl)urea (11g).**

Yield: 99%, as white powder, m.p. 62-63 °C. R_f 0.42 (*n*-C₆H₁₄/EtOAc, 2:1). ¹H NMR (300 MHz, CDCl₃) (δ, ppm): 5.79-5.66 (m, 1H, CH=); 5.14 (br.s, 2H, 2NH); 5.06-4.98 (m, 2H, CH₂=); 3.15 (t, J = 6.4 Hz, 2H, CH₂N); 2.18 (dt, J = 6.7, 6.9 Hz, 2H, CH₂CH=); 1.28 (s, 9H, *t*Bu). ¹³C NMR (75 MHz, CDCl₃) (δ, ppm): 158.08; 135.68; 116.57; 49.93; 39.15; 34.54; 29.51 3C. C₉H₁₈N₂O (170.3): calcd. C 63.49, H 10.66, N 16.45; found C 63.42, H 10.70, N 16.43.

Ethyl *N*-{[(1-phenyl-3-butenyl)amino]carbonyl}carbamate (16a).

Yield: 90%, as crystalline solid, m.p. 80-81 °C (*n*-C₆H₁₄). R_f 0.52 (EtOAc). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 8.31 (d, *J* = 7.3 Hz, 1H, NHCH); 7.98 (s, 1H, NH); 7.37-7.25 (m, 5H, Ph); 5.78-5.67 (m, 1H, CH=); 5.17-5.10 (m, 2H, CH₂=); 5.05 (dd, *J* = 7.0, 14.3 Hz, 1H, CHPh); 4.21 (q, *J* = 7.0 Hz, 2H, CH₂O); 2.60 (t, *J* = 6.7 Hz, 2H, CH₂); 1.31 (t, *J* = 7.0 Hz, 3H, CH₃). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 154.37; 152.61; 141.68; 133.61; 128.49 2C; 127.20; 126.27 2C; 118.36; 62.15; 53.45; 41.10; 14.18. C₁₄H₁₈N₂O₃ (262.3): calcd. C 64.10, H 6.92, N 10.68; found C 64.12, H 7.00, N 10.62.

Benzyl *N*-{[(1-phenyl-3-butenyl)amino]carbonyl}carbamate (16b).

Yield: 88%, as crystalline solid, m.p. 84-85 °C (*n*-C₆H₁₄). R_f 0.50 (*n*-C₆H₁₄/EtOAc, 3:1). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 8.28 (d, *J* = 7.8 Hz, 1H, NHCH); 8.21 (s, 1H, NH); 7.42-7.26 (m, 10H, 2Ph); 5.73 (ddt, *J* = 7.0, 10.0, 17.1 Hz, 1H, CH=); 5.20 (s, 2H, PhCH₂O); 5.17-5.10 (m, 2H, CH₂=); 5.05 (dd, *J* = 7.0, 14.4 Hz, 1H, CHPh); 2.61 (t, *J* = 6.9 Hz, 2H, CH₂). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 154.17; 152.50; 141.59; 134.98; 133.61; 128.60 2C; 128.50 3C; 127.99 2C; 127.33; 126.31 2C; 118.37; 67.55; 53.55; 41.01. C₁₉H₂₀N₂O₃ (324.4): calcd. C 70.35, H 6.21, N 8.64; found C 70.41, H 6.30, N 8.64.

***N*-(*tert*-Butyl)-*N'*-(1-phenyl-3-butenyl)urea (16c).**

Yield: 99%, as crystalline solid, mp 162-163 °C (*n*-C₆H₁₄). R_f 0.48 (*n*-C₆H₁₄/EtOAc, 2:1). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 7.34-7.22 (m, 5H, Ph); 5.68 (ddt, *J* = 6.2, 10.2, 16.8 Hz, 1H, CH=); 5.18 (d, *J* = 6.7 Hz, 1H, NHCH); 5.10-5.04 (m, 2H, CH₂=); 4.73-4.68 (m, 2H, CHPh and NH); 2.47 (t, *J* = 7.0 Hz, 2H, CH₂); 1.23 (s, 9H, *t*Bu). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 157.21; 142.90; 134.18; 128.45 2C; 127.04; 126.29 2C; 118.01; 53.86; 50.10; 41.89; 29.33 3C. C₁₅H₂₂N₂O (246.3): calcd. C 73.13, H 9.00, N 11.37; found C 73.18, H 9.07, N 11.24.

Benzyl *N*-{[(1-phenyl-3-butynyl)amino]carbonyl}carbamate (16A).

Yield: 90%, as crystalline solid, m.p. 117-118 °C (*n*-C₆H₁₄/EtOAc). R_f 0.2 (*n*-C₆H₁₄/EtOAc, 3:1). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 8.51 (d, *J* = 7.9 Hz, 1H, NHCH); 7.99 (s, 1H, NH); 7.40-7.29 (m, 10H, 2Ph); 5.19 (s, 2H, PhCH₂O); 5.16 (dd, *J* = 6.1, 14.0 Hz, 1H, CHPh); 2.81 (ddd, *J* = 2.4, 6.3, 16.7 Hz, 1H, CH_AH_B); 2.71 (ddd, *J* = 2.4, 5.3, 16.7 Hz, 1H, CH_AH_B). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 154.08; 152.37; 140.22; 134.88; 128.65 2C; 128.60; 128.57 2C; 128.11 2C; 127.74; 126.41 2C; 79.63; 71.51; 67.74; 52.14; 26.40. C₁₉H₁₈N₂O₃ (322.4): calcd. C 70.79, H 5.63, N 8.69; found C 70.91, H 5.57, N 8.71.

***N*-(1-Allyl-1-phenyl-3-butenyl)-*N'*-(2-chlorophenyl)urea (20a).**

Yield: 99%, as crystalline solid, m.p. 161-162 °C (*n*-C₆H₁₄). R_f 0.48 (*n*-C₆H₁₄/EtOAc, 4:1).

¹H NMR (400 MHz, CDCl₃) (δ, ppm): 8.05 (d, *J* = 8.2 Hz, 2H, Ar); 7.45-7.43 (m, 2H, Ph); 7.38-7.34 (m, 2H, Ph); 7.28-7.24 (m, 2H, Ph and Ar); 7.17 (td, *J* = 1.3, 8.4 Hz, 1H, Ar); 6.91 (td, *J* = 1.3, 7.7 Hz, 1H, Ar); 6.87 (br.s, 1H, NHAr); 5.63 (ddt, *J* = 7.2, 10.4, 16.1 Hz, 2H, 2CH=); 5.45 (br.s, 1H, NH); 5.14-5.09 (m, 4H, 2CH₂=); 2.92 (dd, *J* = 6.8, 13.6 Hz, 2H, CH₂); 2.69 (dd, *J* = 7.5, 13.6 Hz, 2H, CH₂). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 154.04; 143.61; 135.65; 132.71 2C; 128.86; 128.54 2C; 127.36; 127.18; 126.00 2C; 123.29; 122.82; 121.68; 119.43 2C; 59.76; 42.78 2C. C₂₀H₂₁ClN₂O (340.8): calcd. C 70.48, H 6.21, N 8.22; found C 70.54, H 6.25, N 8.17.

2-Methoxyethyl *N*-{[(1-allyl-1-phenyl-3-butenyl)amino]carbonyl}carbamate (20b).

Yield: 90%, as oil. R_f 0.57 (*n*-C₆H₁₄/EtOAc, 1:1). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 8.28 (s, 1H, NH); 8.26 (s, 1H, NH); 7.38-7.33 (m, 4H, Ph); 7.26-7.21 (m, 1H, Ph); 5.64-5.54 (m, 2H, 2CH=); 5.16-5.09 (m, 4H, 2CH₂=); 4.29-4.27 (m, 2H, CH₂OC(O)); 3.60-3.57 (m, 2H, CH₂OMe); 3.37 (s, 3H, Me); 2.96 (dd, *J* = 6.7, 14 Hz, 2H, CH₂ Allyl); 2.82 (dd, *J* = 7.9, 13.6 Hz, 2H, CH₂ Allyl). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 154.44; 151.69; 143.56; 132.84 2C; 128.09 2C; 126.54; 125.40 2C; 119.00 2C; 69.94; 64.88; 60.73; 58.90; 42.70 2C. C₁₈H₂₄N₂O₄ (332.4): calcd. C 65.04, H 7.28, N 8.43; found C 65.12, H 7.17, N 8.46.

***N*-(1-Allyl-1-phenyl-3-butenyl)-*N'*-(*tert*-butyl)urea (20c).**

Yield: 70%, as white solid, m.p. 195-197 °C. R_f 0.33 (*n*-C₆H₁₄/EtOAc, 6:1). ¹H NMR (300 MHz, CDCl₃) (δ, ppm): 7.49-7.38 (m, 4H, Ph); 7.34-7.29 (m, 1H, Ph); 5.72-5.58 (m, 2H, 2CH=); 5.18-5.13 (m, 4H, 2CH₂=); 4.57 (s, 1H, NH); 4.08 (s, 1H, NH); 2.84 (dd, *J* = 6.7, 13.4 Hz, 2H, 2CH_AH_B); 2.68 (dd, *J* = 7.7, 13.4 Hz, 2H, 2CH_AH_B); 1.21 (s, 9H, *t*Bu). ¹³C NMR (75 MHz, CDCl₃) (δ, ppm): 156.36; 144.18; 133.03 2C; 128.40 2C; 127.07; 126.12 2C; 119.25 2C; 59.14; 50.22; 43.02 2C; 29.22 3C. C₁₈H₂₆N₂O (286.4): calcd. C 75.48, H 9.15, N 9.78; found C 75.52, H 9.18, N 9.65.

***N*-Allyl-*N'*-(1-allyl-1-phenyl-3-butenyl)urea (20d).**

Yield: 85%, as crystalline solid, m.p. 125-126 °C (*n*-C₆H₁₄:EtOAc). R_f 0.8 (*n*-C₆H₁₄/EtOAc, 1:1). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 7.37-7.31 (m, 4H, Ph); 7.25-7.22 (m, 1H, Ph); 5.73 (ddt, *J* = 5.1, 10.5, 17.2 Hz, 1H, CH= AllylN); 5.63-5.53 (m, 2H, 2CH= Allyl₂C); 5.21 (s, 1H, NH); 5.10-5.00 (m, 6H, 3CH₂=); 4.84 (br. s, 1H, NHAllyl); 3.65 (t, *J* = 5.4 Hz, 2H, NCH₂); 2.85 (dd, *J* = 6.7, 13.7 Hz, 2H, CH₂); 2.62 (dd, *J* = 7.6, 13.7 Hz, 2H, CH₂). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 157.19; 144.58; 135.41; 133.22 2C; 128.19 2C; 126.69; 125.80 2C; 118.84 2C; 114.92; 59.20; 42.78 2C; 42.46. C₁₇H₂₂N₂O (279.4): calcd. C 75.52, H 8.20, N 10.36; found C 75.59, H 8.14, N 10.40.

***N*-(1-Allyl-1-phenyl-3-butenyl)-*N'*-methylurea (20e).**

Yield: 98%, as crystalline solid, m.p. 169-170 °C (*n*-C₆H₁₄:EtOAc). R_f 0.41 (*n*-C₆H₁₄/EtOAc/DCM, 1:1:1). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 7.35-7.30 (m, 4H, Ph); 7.23-7.20 (m, 1H, Ph); 5.62-5.51 (m, 2H, 2CH=); 5.08-5.04 (m, 5H, 2CH₂= and NH); 4.54 (br.s, 1H, NH); 2.82 (dd, *J* = 6.5, 13.6 Hz, 2H, 2CH_AH_B); 2.61 (dd, *J* = 7.9, 13.6 Hz, 2H, 2CH_AH_B); 2.57 (s, 3H, NMe). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 158.04; 144.56; 133.25 2C; 128.26 2C; 126.77; 125.84 2C; 118.90 2C; 59.12; 43.00 2C; 26.87. C₁₅H₂₀N₂O (244.3): calcd. C 73.74, H 8.25, N 11.47; found C 73.77, H 8.17, N 11.42.

General procedure for NBS mediated cyclobromocarbamation, synthesis of bromides 12a-g, 17a-d, 21a-d, 25a,b.

2-Methoxyethyl *N*-[6-(bromomethyl)-1,3-oxazinan-2-yliden]carbamate (12a).

To a solution of urea **11a** (0.37 g, 1.7 mmol) in DCM (4 ml) NBS (0.36 g, 2.04 mmol) was added with stirring at ambient temperature. The solution was stirred for 40 min. until disappearance of starting urea **11a**. After evaporation of DCM the residue was dissolved in a mixture of Et₂O/EtOAc (4:1, 15 ml) and 10% solution of NaOH (5 ml) was added. The mixture was vigorously stirred for 10 min, the organic layer was separated, dried with K₂CO₃, evaporated and purified through a column of silica gel (EtOAc/MeOH, 10:1) to furnish **12a** (0.43 g, 85%) as oil. R_f 0.20 (MeOH/EtOAc,10:1). ¹H NMR (300 MHz, CDCl₃) (δ, ppm): 9.42 (br.s, 1H, NH); 4.44-4.37 (m, 1H, CHO); 4.06-4.03 (m, 2H, CH₂OC(O)); 3.51-3.36 (m, 6H, CH₂Br, CH₂N, CH₂OMe); 3.22 (s, 3H, OMe); 2.20-2.12 (m, 1H, CH_AH_BCHO); 1.94-1.80 (m, 1H, CH_AH_BCHO). ¹³C NMR (75 MHz, CDCl₃) (δ, ppm): 163.88; 161.77; 74.89; 70.26; 63.76; 58.55; 37.33; 32.00; 24.05. C₉H₁₅BrN₂O₄ (295.1): calcd. C 36.63, H 5.12, N 9.49; found C 36.72, H 5.16, N 9.37.

***N*-[6-(Bromomethyl)-1,3-oxazinan-2-yliden]-*N*-(*tert*-butyl)amine (12g).**

Yield: 99% as a white solid, m.p. 112–113 °C. R_f 0.4 (EtOAc). ¹H NMR (300 MHz, CDCl₃) (δ, ppm): 4.28-4.20 (m, 1H, CHO); 4.13 (br.s, 1H, NH); 3.41 (d, *J* = 5.6 Hz, 2H, CH₂N); 3.37-3.25 (m, 2H, CH₂Br); 1.94-1.86 (m, 1H, CH_AH_BCHO); 1.71-1.58 (m, 1H, CH_AH_BCHO); 1.26 (s, 9H, *t*Bu). ¹³C NMR (75 MHz, CDCl₃) (δ, ppm): 150.82; 74.26; 50.37; 40.99; 33.87; 29.44 3C; 26.37. C₉H₁₇BrN₂O (249.1): calcd. C, 43.39; H, 6.88; N, 11.24; found C, 43.41; H, 6.89; N, 11.20.

Ethyl *N*-[6-(bromomethyl)-4-phenyl-1,3-oxazinan-2-yliden]carbamate (17a).

Yield: 99% as oil, mixture of *cis/trans*-isomers (2.6:1). R_f 0.8 (EtOAc). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 9.84 (br.s, 1H, NH); 7.41-7.24 (m, 5H, Ph); 4.85 (dd, *J* = 3.6, 5.6 Hz, 0.28H, PhCH *trans*); 4.69 (dd, *J* = 4.6, 11.5 Hz, 0.72H, PhCH *cis*); 4.63 (dddd, *J* = 2.2, 4.4, 6.6, 9.3 Hz, 0.72H, CHO *cis*); 4.42-

4.36 (m, 0.28H, CHO trans); 4.11 (q, $J = 7.1$ Hz, 0.28x2H, OEt trans); 4.08 (q, $J = 7.1$ Hz, 0.72x2H, OEt cis); 3.61 (dd, $J = 4.4$, 10.7 Hz, 0.72H, $\text{CH}_A\text{H}_B\text{Br}$ cis); 3.25 (dd, $J = 4.6$, 11.0 Hz, 0.28H, $\text{CH}_A\text{H}_B\text{Br}$ trans); 3.47 (dd, $J = 6.8$, 11.0 Hz, 1H, $\text{CH}_A\text{H}_B\text{Br}$ cis and $\text{CH}_A\text{H}_B\text{Br}$ trans); 2.54 (ddd, $J = 2.2$, 4.6, 13.9 Hz, 0.72H, $\text{CH}_A\text{H}_B\text{CHO}$ cis); 2.43 (ddd, $J = 5.6$, 9.8, 13.9 Hz, 0.28H, $\text{CH}_A\text{H}_B\text{CHO}$ trans); 2.23 (dt, $J = 3.2$, 13.9 Hz, 0.28H, $\text{CH}_A\text{H}_B\text{CHO}$ trans); 1.91 (dt, $J = 11.5$, 13.9 Hz, 0.72H, $\text{CH}_A\text{H}_B\text{CHO}$ cis); 1.27 (t, $J = 7.1$ Hz, 0.28x3H, EtO trans); 1.25 (t, $J = 7.1$ Hz, 0.72x3H, EtO cis). $\text{C}_{14}\text{H}_{17}\text{BrN}_2\text{O}_3$ (341.2): calcd. C, 49.28; H, 5.02; N, 8.21; found C, 49.34; H, 5.07; N, 8.16.

Benzyl *N*-[6-(bromomethyl)-4-phenyl-1,3-oxazinan-2-yliden]carbamate (17b).

Yield: 99% as oil, mixture of *cis/trans*-isomers (2.4:1). The individual isomers were separated by column chromatography on silica gel (*n*- C_6H_{14} /EtOAc, 3:2), R_f ***trans*-17b** 0.23; R_f ***cis*-17b** 0.14. The relative configurations were assigned by the NOESY experiment.

Minor ***trans*-17b** ^1H NMR (400 MHz, CDCl_3) (δ , ppm): 10.02 (br.s, 1H, NH); 7.44-7.40 (m, 4H, Ph); 7.37-7.26 (m, 6H, Ph); 5.18 (d, $J = 12.6$ Hz, 1H, $\text{PhCH}_A\text{H}_B\text{O}$); 5.14 (d, $J = 12.7$ Hz, 1H, $\text{PhCH}_A\text{H}_B\text{O}$); 4.88 (dd, $J = 3.4$, 5.6 Hz, 1H, PhCHN); 4.46-4.40 (m, 1H, CHO); 3.55 (dd, $J = 4.7$, 11.1 Hz, 1H, $\text{CH}_A\text{H}_B\text{Br}$); 3.80 (dd, $J = 6.5$, 11.1 Hz, 1H, $\text{CH}_A\text{H}_B\text{Br}$); 2.45 (ddd, $J = 5.8$, 10.0, 14.0 Hz, 1H, $\text{CH}_A\text{H}_B\text{CHO}$); 2.26 (dt, $J = 3.2$, 14.0 Hz, 1H, $\text{CH}_A\text{H}_B\text{CHO}$). ^{13}C NMR (100 MHz, CDCl_3) (δ , ppm): 163.91; 162.04; 140.06; 136.68; 129.12 2C; 128.39; 128.28 2C; 127.72; 127.67 2C; 125.67 2C; 71.77; 66.96; 50.93; 32.38; 31.62. $\text{C}_{19}\text{H}_{19}\text{BrN}_2\text{O}_3$ (403.3): calcd. C, 56.59; H, 4.75; N, 6.95; found C, 56.48; H, 4.67; N, 6.89.

Major ***cis*-17b** ^1H NMR (400 MHz, CDCl_3) (δ , ppm): δ 9.80 (br.s, 1H, NH); 7.43-7.37 (m, 5H, Ph); 7.35-7.26 (m, 5H, Ph); 5.16 (d, $J = 12.6$ Hz, 1H, $\text{PhCH}_A\text{H}_B\text{O}$); 5.10 (d, $J = 12.6$ Hz, 1H, $\text{PhCH}_A\text{H}_B\text{O}$); 4.70 (dd, $J = 4.6$, 11.6 Hz, 1H, PhCHN); 4.66-4.62 (m, 1H, CHO); 3.61 (dd, $J = 4.4$, 10.9 Hz, 1H, $\text{CH}_A\text{H}_B\text{Br}$); 3.50 (dd, $J = 6.4$, 10.9 Hz, 1H, $\text{CH}_A\text{H}_B\text{Br}$); 2.52 (ddd, $J = 2.1$, 4.7, 14.0 Hz, 1H, $\text{CH}_A\text{H}_B\text{CHO}$); 1.93 (dt, $J = 11.6$, 14.0 Hz, 1H, $\text{CH}_A\text{H}_B\text{CHO}$). ^{13}C NMR (100 MHz, CDCl_3) (δ , ppm): 138.92; 136.65; 129.22 2C; 128.83; 128.22 2C; 127.63; 127.52; 125.87; 75.28; 66.75; 53.93; 34.59; 31.99. $\text{C}_{19}\text{H}_{19}\text{BrN}_2\text{O}_3$ (403.3): calcd. C, 56.59; H, 4.75; N, 6.95; found C, 56.63; H, 4.70; N, 6.97.

***N*-[6-(Bromomethyl)-4-phenyl-1,3-oxazinan-2-yliden]-*N*-(*tert*-butyl)amine (17c).**

Yield: 95% as oil, mixture of *cis/trans*-isomers (3:1). The major ***cis*-17c** (as oil) was separated by column chromatography on silica gel in EtOAc. Minor more polar ***trans*-17c** always was eluted in the mixture with residual ***cis*-17c**. R_f ***cis*-17c** 0.21; R_f ***trans*-17b** 0.10 (EtOAc). The relative configurations were assigned by analogy.

cis-17c: ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 7.34-7.30 (m, 4H, Ph); 7.25-7.21 (m, 1H, Ph); 5.24 (br.s, 1H, NH); 4.58 (dd, *J* = 4.6, 11.3 Hz, 1H, CHPh); 4.47 (dtd, *J* = 2.2, 4.8, 10.2 Hz, 1H, CHO); 3.47 (dd, *J* = 4.9, 10.9 Hz, 1H, CH_AH_BBr); 3.43 (dd, *J* = 6.2, 10.9 Hz, 1H, CH_AH_BBr); 2.27 (ddd, *J* = 2.2, 4.5, 13.3 Hz, 1H, CH_AH_B cycle); 2.27 (dt, *J* = 11.5, 13.1 Hz, 1H, CH_AH_B cycle); 1.37 (s, 9H, *t*Bu). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 151.56; 144.59; 128.35 2C; 126.80; 126.17 2C; 74.71; 55.33; 50.94; 36.08; 33.85; 29.53 3C. C₁₅H₂₁BrN₂O (325.2): calcd. C, 55.39; H, 6.51; N, 8.61; found C, 55.43; H, 6.46; N, 8.73.

***N*-[6-(bromomethyl)-4-phenyl-1,3-oxazinan-2-yliden]-*N*-methylamine (17d).**

Yield: 90% as solid, mixture of *cis/trans*-isomers (2.3:1). R_f = 0.4 (EtOAc). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 7.36–7.21 (m, 5H, Ph); 4.77 (dd, *J* = 3.5, 5.5 Hz, 0.3H, PhCH *trans*); 4.59 (dd, *J* = 4.6, 11.3 Hz, 0.7H, PhCH *cis*); 4.47 (dtd, *J* = 2.2, 5.3, 11.3 Hz, 0.7H, CHO *cis*); 4.32 (br.s, 1H, NH), 4.20-4.14 (m, 0.3H, CHO *trans*); 3.45 (d, *J* = 5.3 Hz, 0.7x2H, CH₂Br *cis*); 3.44-3.40 (m, 0.6H, CH₂Br *trans*); 2.83 (s, 0.3x3H, Me *trans*); 2.81 (s, 0.7x3H, Me *cis*); 2.29 (ddd, *J* = 2.3, 4.4, 13.3 Hz, 0.7H, CH_AH_BCHO *cis*); 2.19 (ddd, *J* = 5.7, 10.1, 13.6 Hz, 0.3H, CH_AH_BCHO *trans*); 1.96 (dt, *J* = 3.3, 13.6 Hz, 0.3H, CH_AH_BCHO *trans*); 1.96 (dt, *J* = 11.4, 13.3 Hz, 0.7H, CH_AH_BCHO *cis*). C₁₂H₁₅BrN₂O (283.2): calcd. C, 50.90; H, 5.34; N, 9.89; found C, 50.86; H, 5.52; N, 9.84.

***trans-N*-[4-Allyl-6-(bromomethyl)-4-phenyl-1,3-oxazinan-2-yliden]-2-chloroaniline (21a).**

Yield: 85% as solid, mixture of *cis/trans*-isomers (1:20). Recrystallization from *n*-C₆H₁₄/EtOAc gave pure *trans*-**21a**, m.p. 91-92 °C (*n*-C₆H₁₄/EtOAc, 6:1). R_f 0.55 (*n*-C₆H₁₄/EtOAc, 6:1). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 8.67 (br.s, 1H, Ar); 7.46-7.39 (m, 5H, Ph); 7.32-7.27 (m, 2H, Ar); 6.97 (t, *J* = 7.3 Hz, 1H, Ar); 6.60 (br.s, 1H, NH); 5.88-5.78 (br.m, 1H, CH=); 5.16-5.12 (br.m, 2H, CH₂=); 4.04-4.01 (m, 1H, CHO); 3.47 (br.m, 2H, CH₂Br); 2.84-2.80 (br.m, 1H, CH_AH_B allyl); 2.60 (br.dd, *J* = 7.9, 12.7 Hz, 1H, CH_AH_B allyl); 2.42 (d, *J* = 13.0 Hz, 1H, CH_AH_BCHO); 2.02 (d, *J* = 12.4, 1H, CH_AH_BCHO). All signals in ¹³C are broaden except at 71.77 ppm, ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 146.31; 146.20; 137.15; 134.19; 128.70; 128.30 2C; 127.37; 126.67; 126.62; 126.03 2C; 121.69; 119.93; 118.07; 71.77; 59.08; 48.97; 37.95; 33.93. C₂₀H₂₀BrClN₂O (419.7): calcd. C, 57.23; H, 4.80; N, 6.67; found C, 57.09; H, 4.75; N, 6.70.

***trans*-2-Methoxyethyl *N*-[4-allyl-6-(bromomethyl)-4-phenyl-1,3-oxazinan-2-yliden]carbamate (21b).**

Yield: 98% as oil, mixture of *cis/trans*-isomers (1:15). R_f 0.21 (*n*-C₆H₁₄/EtOAc, 1:1). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 10.10 (br.s, 1H, NH); 7.38-7.22 (m, 5H, Ph); 5.42-5.31 (m, 1H, CH=); 5.24-5.20

(m, 2H, CH₂=); 4.22 (t, *J* = 4.8 Hz, 2H, CH₂OC(O)); 4.06-3.99 (m, 1H, CHO); 3.60 (t, *J* = 4.8 Hz, 2H, CH₂OMe); 3.45-3.38 (m, 2H, CH₂Br); 3.35 (s, 3H, Me); 2.86 (dd, *J* = 5.1, 13.7 Hz, 1H, CH_AH_B allyl); 2.57 (dd, *J* = 2.2, 14.0 Hz, 1H, CH_AH_BCHO); 2.47 (dd, *J* = 9.2, 14.0 Hz, 1H, CH_AH_BCHO); 2.10 (dd, *J* = 12.1, 13.7 Hz, 1H, CH_AH_B allyl). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 164.10; 161.57; 142.15; 129.81; 128.90 2C; 127.79; 125.15 2C; 121.89; 72.26; 70.37; 64.18; 58.78; 58.72; 46.87; 38.10; 32.28. C₁₈H₂₃BrN₂O₄ (411.3): calcd. C, 52.56; H, 5.64; N, 6.81; found C, 52.36; H, 5.71; N, 6.93.

***trans-N*-[4-Allyl-6-(bromomethyl)-4-phenyl-1,3-oxazinan-2-yliden]-*N*-(*tert*-butyl)amine (21c).**

Yield: 89% as oil, mixture of *cis/trans*-isomers (1:19). R_f 0.32 (*n*-C₆H₁₄/EtOAc, 4:1). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 7.37-7.30 (m, 4H, Ph); 7.20 (t, *J* = 7.0 Hz, 1H, Ph); 5.85-5.75 (m, 1H, CH=); 5.03-4.99 (m, 2H, CH₂=); 3.83-3.77 (m, 1H, CHO); 3.33 (d, *J* = 5.4 Hz, 2H, CH₂Br); 2.62 (dd, *J* = 6.0, 13.7 Hz, 1H, CH_AH_B allyl); 2.46 (dd, *J* = 8.0, 13.7 Hz, 1H, CH_AH_B allyl); 2.19 (dd, *J* = 1.6, 12.9 Hz, 1H, CH_AH_BCHO); 1.79 (t, *J* = 12.7 Hz, 1H, CH_AH_BCHO); 1.41 (s, 9H, *t*Bu). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 149.01 br.; 147.85 br.; 135.09 br.; 128.07 2C; 126.24 3C; 117.31 br.; 71.16 br.; 58.72; 50.53 br.; 49.36 br.; 37.97 br.; 34.49 br.; 29.38 3C. C₁₈H₂₅BrN₂O (365.3): calcd. C, 59.18; H, 6.90; N, 7.67; found C, 59.32; H, 6.98; N, 7.54.

***trans-N*-[4-Allyl-6-(bromomethyl)-4-phenyl-1,3-oxazinan-2-yliden]-2-propen-1-amine (21d).**

Yield: 72% as oil, mixture of *cis/trans*-isomers (1:10). R_f 0.58 (*n*-C₆H₁₄/EtOAc, 1:1). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 7.37-7.29 (m, 4H, Ph); 7.20 (t, *J* = 7.0 Hz, 1H, Ph); 5.97 (ddt, *J* = 5.3, 10.2, 17.1 Hz, 1H, CH= N-allyl); 5.85-5.75 (m, 1H, CH=); 5.24 (d, *J* = 17.2 Hz, 1H, CH_AH_B= N-allyl); 5.14 (d, *J* = 10.2 Hz, 1H, CH_AH_B= N-allyl); 5.03-5.00 (m, 2H, CH₂=); 3.93 (br.s, 1H, NH); 3.89 (d, *J* = 5.0 Hz, 2H, CH₂Br); 3.85-3.79 (m, 1H, CHO); 3.34-3.33 (m, 2H, CH₂N); 2.59 (dd, *J* = 5.9, 13.6 Hz, 1H, CH_AH_B, AllCPh); 2.47 (dd, *J* = 8.0, 13.6 Hz, 1H, CH_AH_B, AllCPh); 2.19 (dd, *J* = 1.8, 13.3 Hz, 1H, CH_AH_BCHO); 1.82 (dd, *J* = 12.1, 13.3 Hz, 1H, CH_AH_BCHO). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 150.24, 147.74, 135.65, 135.00, 128.07 2C, 126.25, 126.12 2C, 117.38, 115.38, 71.26, 58.21, 49.14, 44.15, 37.74, 34.50. C₁₇H₂₁BrN₂O (349.3): calcd. C, 58.46; H, 6.06; N, 8.02; found C, 58.45; H, 6.14; N, 7.57.

***trans-N*-[4-Allyl-6-(bromomethyl)-4-phenyl-1,3-oxazinan-2-yliden]methanamine (21e).**

Yield: 70% as oil, mixture of *cis/trans*-isomers (1:8). R_f 0.1 (EtOAc). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 7.37 (d, *J* = 7.6 Hz, 2H, Ph); 7.33-7.29 (m, 2H, Ph); 7.22-7.18 (m, 1H, Ph); 5.88-5.77 (m, 1H, CH=); 5.05-5.01 (m, 2H, CH₂=); 3.82 (tdt, *J* = 2.3, 5.3, 11.8 Hz, 1H, CHO); 3.35 (dd, *J* = 1.4, 7.8 Hz, 1H, CH_AH_BBr); 3.32 (dd, *J* = 2.6, 7.8 Hz, 1H, CH_AH_BBr); 2.85 (s, 3H, N-Me); 2.61 (dd, *J* = 6.1, 13.7 Hz, 1H, CH_AH_B allyl); 2.49 (dd, *J* = 8.0, 13.7 Hz, 1H, CH_AH_B allyl); 2.19 (dd, *J* = 2.2, 13.4 Hz, 1H,

CH_AH_B cycle); 1.85-1.79 (m, 1H, CH_AH_B cycle). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 151.30; 147.75; 134.98; 128.06 2C; 126.25; 126.08 2C; 117.40; 71.19; 58.13; 49.10; 37.70; 34.55; 28.40. C₁₅H₁₉BrN₂O (322.2): calcd. C, 55.74; H, 5.92; N, 8.67; found C, 55.83; H, 6.10; N, 8.58.

***N*-[4-Allyl-6-(bromomethyl)-3-(4-methoxybenzyl)-4-phenyl-1,3-oxazinan-2-yliden]-2-methyl-2-propanamine (25a).**

Yield: 77% as oil, mixture of *cis/trans*-isomers (1:12). Recrystallization from *n*-C₆H₁₄/EtOAc gave pure *trans*-**25a**, as solid, m.p. 115-116 °C. R_f 0.26 (*n*-C₆H₁₄/EtOAc, 1:1). ¹H NMR (300 MHz, CDCl₃) (δ, ppm): 7.52-7.29 (m, 7H, Ph and Ar); 6.84 (d, *J* = 8.2 Hz, 2H, Ar); 5.91-5.78 (m, 1H, CH=); 5.23-5.18 (m, 2H, CH₂=); 4.43-4.27 (m, 3H, CH₂Ar and CHO); 3.85 (s, 3H, OMe); 3.48-3.43 (m, 2H, CH₂Br); 3.02 (br.d, *J* = 14.1 Hz, CH_AH_B allyl); 3.88 (br.dd, *J* = 9.3, 14.3 Hz, CH_AH_B allyl); 2.34 (br.t, *J* = 12.8 Hz, CH_AH_B cycle); 2.00 (br.d, *J* = 13.1 Hz, CH_AH_B cycle); 1.28 (s, 9H, *t*Bu). ¹³C NMR (75 MHz, CDCl₃) (δ, ppm): 157.84; 147.21; 146.32; 133.45; 132.48; 129.43 2C; 128.67 2C; 127.20; 126.34 2C; 119.52; 112.82 2C; 70.24; 63.12; 55.14; 51.70; 48.70; 43.72; 40.96; 33.87; 30.65 3C. C₂₆H₃₃BrN₂O₂ (485.4): calcd. C, 64.33; H, 6.85; N, 5.77; found C, 64.43; H, 6.82; N, 5.71.

***N*-[4-Allyl-6-(bromomethyl)-3-(4-methoxybenzyl)-4-phenyl-1,3-oxazinan-2-yliden]-2-propen-1-amine (25b).**

Yield: 72% as oil, mixture of *cis/trans*-isomers (1:10). Recrystallization from *n*-C₆H₁₄/EtOAc gave pure *trans*-**25b**, as solid, m.p. 108-110 °C. R_f 0.32 (*n*-C₆H₁₄/EtOAc, 1:1). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 7.39-7.34 (m, 4H, Ph); 7.31-7.27 (m, 1H, Ph); 7.24 (d, *J* = 8.6 Hz, 2H, Ar); 6.78 (d, *J* = 8.6 Hz, 2H, Ar); 5.95 (ddt, *J* = 5.1, 10.5, 17.2 Hz, 1H, CH=, N-allyl); 5.61 (dddd, *J* = 4.8, 8.1, 9.2, 14.0 Hz, 1H, CH=, allyl); 5.12 (dm, *J* = 16.9 Hz, 1H, CH_AH_B=, N-allyl); 5.08-5.04 (m, 2H, CH₂= allyl); 4.96 (dm, *J* = 10.5 Hz, 1H, CH_AH_B=, N-allyl); 4.79 (d, *J* = 15.6 Hz, 1H, CH_AH_BPh); 4.25 (d, *J* = 15.6 Hz, 1H, CH_AH_BPh); 4.16 (dtd, *J* = 1.9, 5.1, 11.8 Hz, 1H, CHO); 3.91 (dm, *J* = 5.1 Hz, 2H, CH₂Br); 3.77 (s, 3H, OMe); 3.41 (dd, *J* = 5.7, 10.8 Hz, 1H, CH_AH_BN); 3.35 (dd, *J* = 5.1, 10.8 Hz, 1H, CH_AH_BN); 2.89 (dd, *J* = 4.8, 14.6 Hz, 1H, CH_AH_B allyl); 2.77 (dd, *J* = 8.9, 14.6 Hz, 1H, CH_AH_B allyl); 2.28 (dd, *J* = 11.8, 13.3 Hz, 1H, CH_AH_B cycle); 2.04 (dd, *J* = 1.9, 13.6 Hz, 1H, CH_AH_B cycle). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 158.09; 150.94; 145.13; 138.40; 132.98; 131.79; 129.04 2C; 128.78 2C; 127.38; 126.37 2C; 119.61; 113.24 2C; 113.15; 70.56; 63.66; 55.16; 48.87; 48.05; 43.78; 40.60; 33.73. C₂₅H₂₉BrN₂O₂ (469.4): calcd. C, 63.97; H, 6.23; N, 5.97; found C, 63.88; H, 6.25; N, 5.92.

General procedure for phenylselenocyclocarbamation. Synthesis of selenides 30a-c.

2-Methyl-N-{4-phenyl-6-[(phenylselanyl)methyl]-1,3-oxazinan-2-yliden}-2-propanamine (30c).

Urea **16c** (0.368 g, 1.5 mmol) was added to a stirred solution of phenylselanyl chloride (0.383 g, 2.0 mmol, 30% excess) in DCM (10 mL)/MeCN (1 ml). The reaction mixture was stirred for 10 min. *i*Pr₂EtN (0.258 g, 0.33 mL, 2.0 mmol) was added and the mixture was stirred for additional 2 h (TLC control) and then washed with NaOAc solution, dried with Na₂SO₄ and passed through the short pad of silica gel, washed with EtOAc/MeOH (9:1) and evaporated under reduced pressure to gave **30c** (0.51 g, 85%) as slowly solidifying oil, mixture of *cis/trans*-isomers (1.9:1),ⁱⁱⁱ R_f 0.5 (EtOAc/MeOH, 9:1). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 7.55-7.53 (m, 0.66x2H, Ph, *cis*); 7.45-7.42 (m, 0.33x2H, Ph, *trans*); 7.35-7.19 (m, 8H, 2Ph, *cis* and *trans*); 4.65 (t, *J* = 6.4 Hz, 0.33x1H, CHN, *trans*); 4.52 (dd, *J* = 4.4, 11.4 Hz, 0.66x1H, CHN, *cis*); 4.39 (dddd, *J* = 2.2, 6.0, 11.4, 6.7 Hz, 0.66x1H, CHO, *cis*); 4.12 (dtd, *J* = 4.8, 8.6, 12.1 Hz, 0.33x1H, CHO, *trans*); 3.82 (br.s, 1H, NH); 3.13 (dd, *J* = 8.8, 16.7 Hz, 0.33x1H, CH_AH_BSePh, *trans*); 3.11 (dd, *J* = 6.8, 12.8 Hz, 0.66x1H, CH_AH_BSePh, *cis*); 3.00 (dd, *J* = 5.8, 12.8 Hz, 0.66x1H, CH_AH_BSePh, *cis*); 2.96 (dd, *J* = 8.8, 17.0 Hz, 0.33x1H, CH_AH_BSePh, *trans*); 2.33 (ddd, *J* = 2.3, 4.6, 13.4 Hz, 0.66x1H, CH_AH_BCHO, *cis*); 2.08 (ddd, *J* = 7.5, 11.7, 17.8 Hz, 0.33x1H, CH_AH_BCHO, *trans*); 1.97 (dt, *J* = 4.8, 17.8 Hz, 0.33x1H, CH_AH_BCHO, *trans*); 1.45 (dt, *J* = 11.4, 13.4 Hz, 0.66x1H, CH_AH_BCHO, *cis*); 1.36 (s, 0.33x9H, *t*Bu *trans*); 1.35 (s, 0.66x9H, *t*Bu *cis*). MS (70 eV, EI): m/z (%) = 402/400 (M⁺, 1.8/0.9); 314(15); 265(15); 189(21); 157(22); 155(15); 154(43); 147(12); 146(100); 145(18); 132(16); 129(25); 128(16); 117(29); 115(18); 106(70); 105(36); 104(41); 91(18); 79(22); 78(13); 77(49); 58(32); 51(14). HRMS (ESI): calcd. for C₂₁H₂₆N₂OSe (M+H) 403.1283, found: 403.1284.

N-{6-[(Phenylselanyl)methyl]-1,3-oxazinan-2-yliden}-1-adamantanamine (30a).

Yield: 73% as a colorless solid, m.p. 95-97 °C. R_f 0.15 (EtOAc/*i*PrOH/Et₃N, 14:7:1). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 7.56-7.50 (m, 2H, Ph); 7.32-7.22 (m, 3H, Ph); 4.28-4.19 (m, 1H, CHO); 3.38 (ddd, *J* = 3.0, 5.9, 14.9 Hz, 1H, CH_AH_BN); 3.30 (ddd, *J* = 5.1, 10.5, 14.9 Hz, 1H, CH_AH_BN); 3.16 (dd, *J* = 7.0, 12.7 Hz, 1H, CH_AH_BSePh); 3.03 (dd, *J* = 5.9, 12.7 Hz, 1H, CH_AH_BSePh); 2.07 (narrow m, 3H, 3CH Ad); 2.01-1.95 (m, 1H, CH_AH_BCHO); 1.93-1.92 (m, 6H, 3CH₂ Ad); 1.71-1.61 (m, 7H, CH_AH_BCHO and 3CH₂ Ad). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 151.27; 132.87 2C; 129.76; 129.11 2C; 127.18; 74.66; 50.77; 42.46 3C; 41.41; 36.34 3C; 32.31; 29.15 3C; 27.73. ⁷⁷Se NMR (95 MHz, CDCl₃) (δ, ppm): 264.44. HRMS Calcd for C₂₁H₂₈N₂OSe: 405.1440(M+H). Found: 405.1430 (MH⁺).

N-{4,4-Dimethyl-6-[(phenylselanyl)methyl]-1,3-oxazinan-2-yliden}-1-adamantanamine (30b).

Yield: 81% as a colorless solid, m.p. 176-177 °C. R_f 0.54 (EtOAc/*i*PrOH, 3:1). ^1H NMR (400 MHz, CDCl_3) (δ , ppm): 8.88 (br.s, 1H, NH); 7.48-7.46 (m, 2H, Ph); 7.26-7.25 (m, 3H, Ph); 4.49-4.43 (m, 1H, CHO); 3.16 (dd, $J = 7.2, 13.0$ Hz, 1H, $\text{CH}_\text{A}\text{H}_\text{B}\text{SePh}$); 3.07 (dd, $J = 5.1, 13.0$ Hz, 1H, $\text{CH}_\text{A}\text{H}_\text{B}\text{SePh}$); 2.03-2.01 (m, 4H, 11H, $\text{CH}_\text{A}\text{H}_\text{B}\text{CHO}$ and 3CH Ad); 1.97-1.88 (m, 6H, 3 CH_2 Ad); 1.69 (dd, $J = 12.2, 13.6$ Hz, 1H, $\text{CH}_\text{A}\text{H}_\text{B}\text{CHO}$); 1.58 (narrow m, 6H, 3 CH_2 Ad); 1.36 (s, 3H, Me); 1.25 (s, 3H, Me). ^{13}C NMR (100 MHz, CDCl_3) (δ , ppm): 156.81; 133.34 2C; 129.43 2C; 128.11; 128.00; 76.11; 54.23; 50.46; 41.54 3C; 39.63; 35.67 3C; 30.80; 29.75; 29.16 3C; 28.97. ^{77}Se NMR (95 MHz, CDCl_3): δ 269.35. HRMS Calcd for $\text{C}_{23}\text{H}_{32}\text{N}_2\text{OSe}$: 433.1754 (M+H). Found: 433.1739 (MH $^+$).

General procedure of selenides 30a-c oxidation to selenoxides and their thermal elimination with formation of enolesters 31a-c.

***N*-(Adamantan-1-yl)-6-methylene-1,3-oxazinan-2-imine (31a).**

A solution of NaIO_4 (0.44 g, 2.28 mmol) in water (5 mL) was added to a mixture of **30a** (0.31 g, 0.76 mmol) in MeOH/DCM (3:2, 10 mL) at 0 °C. The reaction mixture was stirred for 20 min (TLC control). The mixture was diluted with DCM (20 mL) and saturated solution of NH_4Cl (20 mL). The organic phase was separated and aqueous phase extracted with DCM (2x10 mL). The combined extracts were dried over Na_2SO_4 and evaporated to dryness under reduced pressure. The selenoxide was dissolved in dioxane (10 mL) and heated with stirring for 1h at 70 °C. The solvent was evaporated and the residue was purified by FC on silica gel in EtOAc/*n*- C_6H_{14} / Et_3N (10:10:1) to give **31a** (0.025 g, 13%) as a beige solid, m.p. 114-116 °C. R_f 0.63 (EtOAc/*n*- C_6H_{14} / Et_3N , 10:10:1). ^1H NMR (400 MHz, CDCl_3) (δ , ppm): 4.42 (s, 1H, $\text{CH}_\text{A}\text{H}_\text{B}=\text{}$); 4.09 (s, 1H, $\text{CH}_\text{A}\text{H}_\text{B}=\text{}$); 3.32 (t, $J = 6.0$ Hz, 2H, CH_2N); 2.36 (t, $J = 6.0$ Hz, 2H, CH_2CHO); 2.04 (narrow m, 3H, 3CH Ad); 1.92 (narrow m, 6H, 3 CH_2 Ad); 1.63 (narrow m, 6H, 3 CH_2 Ad). ^{13}C NMR (100 MHz, CDCl_3) (δ , ppm): 154.08; 148.76; 89.43; 51.11; 42.23 3C; 41.29; 36.34 3C; 29.43 3C; 26.16. $\text{C}_{15}\text{H}_{22}\text{N}_2\text{O}$ (246.4): calcd. C, 73.13; H, 9.00; N, 11.37; found C, 73.19; H, 9.12; N, 11.26.

***N*-(Adamantan-1-yl)-4,4-dimethyl-6-methylene-1,3-oxazinan-2-imine (31b).**

Yield: 32% as a white solid, m.p. 95-97 °C. R_f 0.66 (EtOAc/*n*- C_6H_{14} / Et_3N , 10:10:1). ^1H NMR (400 MHz, CDCl_3) (δ , ppm): 4.50 (s, 1H, $\text{CH}_\text{A}\text{H}_\text{B}=\text{}$); 4.09 (narrow m, 1H, $\text{CH}_\text{A}\text{H}_\text{B}=\text{}$); 2.18 (s, 2H, CH_2CHO); 2.03 (narrow m, 3H, 3CH Ad); 1.90 (narrow m, 6H, 3 CH_2 Ad); 1.63 (narrow m, 6H, 3 CH_2 Ad); 1.11 (s, 6H, 2Me). ^{13}C NMR (100 MHz, CDCl_3) (δ , ppm): 153.11; 147.92; 90.47; 51.11; 49.46; 42.49 3C; 39.00; 36.40 3C; 29.80 2C; 29.56 3C. $\text{C}_{17}\text{H}_{26}\text{N}_2\text{O}$ (274.4): calcd. C, 74.41; H, 9.55; N, 10.21; found C, 74.25; H, 9.62; N, 10.27.

***N*-(*tert*-Butyl)-*N*-(6-methylene-4-phenyl-1,3-oxazinan-2-yliden)amine (31c).**

Yield: 18% as oil. R_f 0.66 (EtOAc/MeOH, 9:1). ^1H NMR (400 MHz, CDCl_3) (δ , ppm): 7.34-7.33 (m, 4H, Ph); 7.27-7.21 (m, 1H, Ph); 4.57 (dd, $J = 4.5, 9.2$ Hz, 1H, CHN); 4.49 (s, 1H, $\text{CH}_A\text{H}_B=$); 4.19 (br. s, 1H, NH); 4.09 (s, 1H, $\text{CH}_A\text{H}_B=$); 2.74 (dd, $J = 4.5, 14.2$ Hz, 1H, $\text{CH}_A\text{H}_B\text{CHO}$); 2.26 (dd, $J = 9.2, 14.2$ Hz, 1H, $\text{CH}_A\text{H}_B\text{CHO}$); 1.40 (s, 9H, *t*Bu). ^{13}C NMR (100 MHz, CDCl_3) (δ , ppm): 153.02 C; 148.47 C; 144.47 C; 128.24 2CH; 126.69 CH; 126.26 2CH; 90.28 C; 54.80 CH; 50.75 C; 35.03 CH_2 ; 29.23 3CH_3 . MS (70 eV, EI): m/z (%) = 244 (M^+ , 11); 202(6); 189(11); 188(33); 146(20); 145(18); 105(15); 104(100); 103(17); 78(28); 77(22); 32(13). $\text{C}_{15}\text{H}_{20}\text{N}_2\text{O}$ (244.3): calcd. C, 73.74; H, 8.25; N, 11.47; found C, 73.81; H, 8.17; N, 11.37.

***N*-(1-Adamantyl)carbodiimide (32a).**

*t*BuOK (0.168 g, 1.5 mmol) was added to a solution of **31b** (0.274 g, 1.0 mmol) in THF (10 mL) at -30 °C and stirred for 10 min, TLC shows immediate disappearance of the starting **31b**. The reaction mixture was quenched with AcOH (0.108 ml, 1.8 mmol), filtered through a pad of silica gel, washed with EtOAc/*n*- C_6H_{14} (3 x 20 mL), evaporated and subjected to FC on silica gel to yield **32a** (177 mg, 100%) as a white solid, m.p. 136-138 °C. R_f 0.7 (EtOAc/*n*- C_6H_{14} / Et_3N , 10:10:1). ^1H NMR (400 MHz, CDCl_3) (δ , ppm): 3.40 (1H, s), 2.22-2.12 (3H, m), 1.84-1.78 (6H, m), 1.68 (6H, m). ^{13}C NMR (100 MHz, CDCl_3) (δ , ppm): 114.17; 52.97; 42.37 3C; 35.64 3C; 29.43 3C. MS (70 eV, EI): m/z (%) = 177 (30, MH^+); 176(1, M^+); 136(11); 135(100); 108(12); 107(37); 93(79); 92(11); 91(41); 81(24); 80(87); 77(43); 67(24); 51(11); 44(14); 39(15); 28(11). HRMS Calcd for $\text{C}_{11}\text{H}_{16}\text{N}_2$: 177.1386($\text{M}+\text{H}$). Found: 177.1394(MH^+).

Dehydrobromination of *N*-PMB-protected bromides 25a,b and their transformation to enolesters 26a,b; 27a,d and ADP 22c, 22d.

***N*-[4-Allyl-3-(4-methoxybenzyl)-6-methylene-4-phenyl-1,3-oxazinan-2-yliden]-2-methyl-2-propanamine (26a).**

To a solution of bromide **25a** (0.49 g, 1.0 mmol) in THF (5 ml) was added *t*BuOK (0.29 g, 2.6 mmol) at -5 – 0 °C and the mixture was stirred at this temperature for 1h. The progress of the reaction was monitored by TLC (*n*- C_6H_{14} /EtOAc, 2:1). After disappearance of the **25a** the reaction was quenched by addition of AcOH (0.24 ml, 4.0 mmol). The reaction mixture was filtered through the pad of Super Cel Hyflo, evaporated and purified by FC (*n*- C_6H_{14} /EtOAc, 4:1) that finally gave **26a** (0.33 g, 82%) as oil. R_f 0.58 (*n*- C_6H_{14} /EtOAc, 2:1). ^1H NMR (400 MHz, CDCl_3) (δ , ppm): 7.40-7.33 (m, 4H, Ph); 7.28 (t, $J = 7.0$ Hz, 1H, Ph); 7.17 (d, $J = 8.3$ Hz, 2H, Ar); 6.76 (d, $J = 8.3$ Hz, 2H, Ar); 5.77-5.67 (m, 1H, CH=

allyl); 5.14-5.08 (m, 2H, CH₂= allyl); 4.57 (d, *J* = 14.6 Hz, 2H, CH_AH_BAr); 4.47 (s, 1H, CH_AH_B=); 4.05 (d, *J* = 14.6 Hz, 2H, CH_AH_BAr); 3.96 (s, 1H, CH_AH_B=); 3.78 (s, 3H, OMe); 2.88 (d, *J* = 14.6 Hz, 1H, CH_AH_BCO); 2.86-2.83 (m, 2H, CH₂ allyl); 2.64 (d, *J* = 14.6 Hz, 1H, CH_AH_BCO); 1.23 (s, 9H, *t*Bu). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 157.94; 151.63; 144.81; 143.99; 133.52; 132.69; 129.19 2C; 128.33 2C; 127.28; 126.65 2C; 119.32; 112.92 2C; 91.03; 62.33; 55.15; 51.83; 49.14; 42.80; 40.44; 30.92 3C. C₂₆H₃₂N₂O₂ (404.5): calcd. C, 77.19; H, 7.97; N, 6.92; found C, 77.10; H, 8.03; N, 6.94.

***N*-[4-Allyl-3-(4-methoxybenzyl)-6-methylene-4-phenyl-1,3-oxazinan-2-yliden]-2-propen-1-amine (26b).**

Yield: 94% as oil. R_f 0.71 (*n*-C₆H₁₄/EtOAc, 1:1). ¹H NMR (300 MHz, CDCl₃) (δ, ppm): 7.42-7.32 (m, 5H, Ph); 7.25 (d, *J* = 8.6 Hz, 2H, Ar); 6.84 (d, *J* = 8.6 Hz, 2H, Ar); 6.09-5.96 (m, 1H, CH= Nallyl); 5.78-5.64 (m, 1H, CH= allyl); 5.23-5.11 (m, 3H, CH_AH_B= Nallyl and CH₂= allyl); 5.06-5.02 (m, 1H, CH_AH_B= Nallyl); 4.92 (d, *J* = 15.7 Hz, 2H, CH_AH_BAr); 4.57 (s, 1H, CH_AH_B=); 4.23 (d, *J* = 15.7 Hz, 2H, CH_AH_BAr); 4.05 (narrow m, 3H, CH_AH_B= and NCH₂); 3.83 (s, 3H, OMe); 2.98 (d, *J* = 14.5 Hz, 1H, CH_AH_BCO); 2.89 (d, *J* = 5.0 Hz, 2H, CH₂ allyl); 2.77 (d, *J* = 14.6 Hz, 1H, CH_AH_BCO). ¹³C NMR (75 MHz, CDCl₃) (δ, ppm): 158.04; 151.05; 148.34; 142.98; 138.19; 133.01; 131.81; 128.69 2C; 128.39 2C; 127.38; 126.48 2C; 119.43; 113.18 2C; 113.12; 91.66; 62.54; 55.06; 49.01; 47.95; 42.73; 40.17. C₂₅H₂₈N₂O₂ (388.5): calcd. C, 77.29; H, 7.26; N, 7.21; found C, 77.19; H, 7.33; N, 7.22.

***N*-(4-Allyl-6-methylene-4-phenyl-1,3-oxazinan-2-yliden)-2-methyl-2-propanamine (27a).**

To a solution of **26a** (0.41 g, 1.0 mmol) in MeCN (8 ml) was added CAN (1.42 g, 2.6 mmol) and H₂O (3 ml) at 0 °C. The mixture was stirred for 5h and each hour (in first 3h) (0.3 ml) of a solution of NaOAc (0.21 g, 2.6 mmol) in water (0.8 ml) was introduced by pipette to the reaction. Workup: The reaction was diluted with EtOAc (20 ml) and brine (30 ml), organic phase was separated and aqueous extracted with EtOAc (2 x 20 ml). Combined extracts were washed with brine and dried over K₂CO₃ after then evaporated under reduced pressure. The residue was purified by FC on silica gel (*n*-C₆H₁₄/EtOAc, 4:1) that gave deprotected enolester **27a** (0.23 g, 84%) as oil. R_f 0.78 (*n*-C₆H₁₄/EtOAc, 2:1). ¹H NMR (300 MHz, CDCl₃) (δ, ppm): 7.55-7.52 (m, 2H, Ph); 7.43-7.38 (m, 2H, Ph); 7.31-7.26 (m, 1H, Ph); 5.86-5.72 (m, 1H, CH= allyl); 5.07-5.02 (m, 2H, CH₂= allyl); 4.49 (s, 1H, CH_AH_B=); 4.11 (s, 1H, CH_AH_B=); 3.91 (br.s, 1H, NH); 2.77 (d, *J* = 14.2 Hz, 1H, CH_AH_BCO); 2.65-2.53 (m, 3H, CH_AH_BCO and CH₂ allyl); 1.52 (s, 9H, *t*Bu). ¹³C NMR (75 MHz, CDCl₃) (δ, ppm): 152.51; 146.90; 145.80; 134.87; 127.85 2C; 126.09; 125.93 2C; 117.18; 90.49; 58.12; 50.40; 48.26; 37.24; 29.06. C₁₈H₂₄N₂O (284.4): calcd. C, 76.02; H, 8.51; N, 9.85; found C, 76.10; H, 8.45; N, 9.89.

***N*-(4-Allyl-6-methylene-4-phenyl-1,3-oxazinan-2-yliden)-2-propen-1-amine (27b).**

Yield: 68% as oil. R_f 0.4 (*n*-C₆H₁₄/EtOAc, 2:1). ¹H NMR (300 MHz, CDCl₃) (δ, ppm): 7.53-7.51 (m, 2H, Ph); 7.42-7.37 (m, 2H, Ph); 7.31-7.26 (m, 1H, Ph); 6.11-5.99 (m, 1H, CH= Nallyl); 5.84-5.71 (m, 1H, CH= allyl); 5.33 (d, J = 17.2 Hz, 1H, CH_AH_B= Nallyl); 5.22 (d, J = 10.2 Hz, 1H, CH_AH_B= Nallyl); 5.08-5.03 (m, 2H, CH₂= allyl); 4.54 (s, 1H, CH_AH_B=); 4.15 (s, 1H, CH_AH_B=); 4.11 (br.s, 1H, NH); 3.99 (d, J = 5.3 Hz, 2H, CH₂N); 2.78 (d, J = 14.2 Hz, 1H, CH_AH_BCO); 2.67-2.52 (m, 3H, CH_AH_BCO and CH₂ allyl). ¹³C NMR (75 MHz, CDCl₃) (δ, ppm): 152.34; 147.91; 146.53; 135.26; 134.60; 127.86 2C; 126.17; 125.81 2C; 117.37; 115.55; 91.18; 57.64; 48.05; 44.10; 37.08. C₁₇H₂₀N₂O (268.4): calcd. C, 76.09; H, 7.51; N, 10.44; found C, 76.17; H, 7.61; N, 10.38.

Synthesis of enolesters 14, 15, 19.

Benzyl *N*-(6-methylene-1,3-oxazinan-2-yliden)carbamate (14).

*t*BuOK (0.26 g, 2.29 mmol) was added to a solution of **12b** (0.30 g, 0.92 mmol) in THF (7 mL) at 0 °C. After 1 min TLC shows disappearance of the starting **12b** then the reaction was quenched with AcOH (0.17 g, 0.16 mL, 2.75 mmol). The mixture was filtered through a pad of Super Cel, washed with THF (3 x 5 mL), evaporated and subjected to FC to yield **14** (0.217 g, 96%) as a colorless crystals, m.p. 87-89 °C. R_f 0.18 (EtOAc/*n*-C₆H₁₄, 1:1). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 9.23 (br.s, 1H, NH); 7.41-7.39 (m, 2H, Ph); 7.35-7.32 (m, 2H, Ph); 7.30-7.26 (m, 1H, Ph); 5.15 (s, 2H, CH₂Ph); 4.84 (d, J = 1.9 Hz, 1H, CH_AH_B=); 4.43 (m, 1H, CH_AH_B=); 3.45 (t, J = 6.2 Hz, 2H, CH₂N); 2.62 (t, J = 6.2 Hz, 2H, CH₂C=). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 164.15; 160.47; 150.66; 136.74; 128.23 2C; 127.64; 127.52 2C; 95.47; 66.91; 37.89; 24.86. C₁₃H₁₄N₂O₃ (246.3): calcd. C, 63.40; H, 5.73; N, 11.38; found C, 63.50; H, 5.79; N, 11.42.

4-Methyl-*N*-(6-methylene-1,3-oxazinan-2-yliden)benzenesulfonamide (15).

Yield: 92% as crystalline solid, m.p. 170-171 °C. R_f 0.57 (EtOAc). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 8.88 (br.s, 1H, NH); 7.80 (d, J = 7.9 Hz, 2H, Ar); 7.25 (d, J = 7.9 Hz, 2H, Ar); 4.72 (s, 1H, CH_AH_B=); 4.39 (s, 1H, CH_AH_B=); 3.48-3.45 (m, 2H, CH₂N); 2.57-2.54 (m, 2H, CH₂C=); 2.39 (s, 3H, Me). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 154.42; 150.81; 142.65; 139.63; 129.14 2C; 126.68 2C; 95.81; 38.02; 24.53; 21.46. C₁₂H₁₄N₂O₃S (266.3): calcd. C, 54.12; H, 5.30; N, 10.52; found C, 54.17; H, 5.23; N, 10.49.

Benzyl *N*-(6-methylene-4-phenyl-1,3-oxazinan-2-yliden)carbamate (19).

Yield: 97% as oil. R_f 0.8 (EtOAc). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 9.77 (br.s, 1H, NH); 7.41-7.31(m, 7H, Ph); 7.29-7.26 (m, 3H, Ph); 5.18 (d, J = 12.7 Hz, 1H, CH_AH_BPh); 5.12 (d, J = 12.7 Hz, 1H,

CH_AH_BPh); 4.89 (d, *J* = 1.8 Hz, 1H, CH_AH_B=); 4.68 (dd, *J* = 4.9, 8.3 Hz, 1H, CHPh); 4.39 (s, 1H, CH_AH_B=); 2.90 (dd, *J* = 4.8, 14.4 Hz, 1H, CH_AH_BC=); 2.61 (dd, *J* = 8.3, 14.4 Hz, 1H, CH_AH_BC=). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 164.00; 160.22; 149.47; 138.69; 136.55; 129.03 2C; 128.67; 128.19 2C; 127.62; 127.49 2C; 125.82 2C; 96.46; 66.87; 52.89; 33.79. C₁₉H₁₈N₂O₃ (322.4): calcd. C, 70.79; H, 5.63; N, 8.69; found C, 70.84; H, 5.60; N, 8.68.

General procedure of ADPs synthesis from bromourethanes.

2-Methoxyethyl *N*-(4-oxo-1,4,5,6-tetrahydro-2-pyridinyl)carbamate (13a).

A solution of bromide **12a** (0.30 g, 1.0 mmol) in dry DMF (2 ml) was treated with *t*BuOK (0.34 g, 3.0 mmol) at 25 °C and the mixture was stirred for 15 min, when TLC control shows no more starting material, then AcOH (0.15 ml, 2.5 mmol) was added to acidify the potassium salt of **13a**. The mixture was passed through the pad of Super Cel, volatiles were evaporated in vacuum and the residue was subjected to FC on silica gel (EtOAc/MeOH, 9:1) that furnished **13a** (0.206 g, 96%) as crystalline solid, m.p. 145-146 °C. R_f 0.52 (EtOAc/MeOH, 9:1). ¹H NMR (300 MHz, CDCl₃) (δ, ppm): 9.84 (br.s, 1H, NH); 7.89 (s, 1H, NH); 4.88 (d, *J* = 1.4 Hz, 1H, CH=); 4.27-4.24 (m, 2H, CH₂OC=O); 3.60-3.57 (m, 2H, CH₂OMe); 3.51 (td, *J* = 2.2, 7.5 Hz, 2H, CH₂N); 3.33 (s, 3H, OMe); 2.37 (t, *J* = 7.6 Hz, 2H, CH₂C=O). ¹³C NMR (75 MHz, CDCl₃) (δ, ppm): 191.24; 158.31; 154.17; 86.00; 70.10; 64.41; 58.63; 40.39; 34.56. C₉H₁₄N₂O₄ (214.2): calcd. C, 50.46; H, 6.59; N, 13.08; found C, 50.44; H, 6.58; N, 13.14.

Benzyl *N*-(4-oxo-1,4,5,6-tetrahydro-2-pyridinyl)carbamate (13b).

The reaction was carried out in THF at 40 °C for 2h. Yield: 83%, as white solid, m.p. 166-167 °C (EtOAc). R_f 0.51 (EtOAc/MeOH, 6:1). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 9.49 (br.s, 1H, NH); 8.29 (s, 1H, NH); 7.36-7.31 (m, 5H, Ph); 5.17 (s, 2H, CH₂Ph); 5.10 (s, 1H, CH=); 3.54 (t, *J* = 7.3 Hz, 2H, CH₂N); 2.44 (t, *J* = 7.6 Hz, 2H, CH₂C=O). ¹³C NMR (75 MHz, CDCl₃) (δ, ppm): 190.72; 158.61; 154.25; 135.04; 128.56 2C; 128.51; 128.16 2C; 86.10; 67.66; 40.25; 34.25. HRMS Calcd for C₁₃H₁₄N₂O₃: 247.1038 (M+H). Found: 247.1075 (MH⁺).

4-Methyl-*N*-(4-oxo-2-piperidinylidene)benzenesulfonamide (13c).

The reaction was carried out in MeOH at 60 °C for 15 min. Yield: 90%, as white solid, m.p. 97-98 °C (EtOAc). R_f 0.43 (EtOAc). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 8.85 (br.s, 1H, NH); 7.80 (d, *J* = 8.1 Hz, 2H, Ar); 7.28 (d, *J* = 8.1 Hz, 2H, Ar); 3.73-3.69 (m, 2H, CH₂N); 3.35 (s, 2H, CH₂C=N); 2.59 (t, *J* = 6.2 Hz, 2H, CH₂C=O); 2.40 (s, 3H, Me). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 201.43; 162.47; 143.31; 138.74; 129.45 2C; 126.39 2C; 47.13; 38.93; 37.59; 21.51. C₁₂H₁₄N₂O₃S (266.3): calcd. C, 54.12; H, 5.30; N, 10.52; found C, 54.19; H, 5.26; N, 10.59.

6-(2-Iodoanilino)-2,3-dihydro-4(1H)-pyridinone (13d).

Transformation of iodide **12d** was carried out in *i*PrOH at 25 °C for 3h. Yield **13d**: 55%, as light-yellow solid, m.p. 213-214 °C (EtOAc). R_f 0.19 (EtOAc/MeOH, 6:1). ^1H NMR (400 MHz, DMSO- D_6) (δ , ppm): 8.18 (s, 1H, NH); 7.90 (d, $J = 7.9$ Hz, 1H, Ar); 7.40 (t, $J = 7.0$ Hz, 1H, Ar); 7.26 (d, $J = 7.8$ Hz, 1H, Ar); 7.00 (t, $J = 7.0$ Hz, 1H, Ar); 6.62 (s, 1H, NH); 4.13 (s, 1H, CH=); 3.37–3.28 (m, 2H, CH_2N); 2.09 (t, $J = 7.0$ Hz, 2H, $\text{CH}_2\text{C}=\text{O}$). ^{13}C NMR (100 MHz, DMSO- D_6) (δ , ppm): 187.80, 160.39, 139.78, 139.33, 129.11, 127.77, 127.75, 98.33, 82.10, 39.73, 35.45. $\text{C}_{11}\text{H}_{11}\text{IN}_2\text{O}$ (314.1): calcd. C, 42.06; H, 3.53; N, 8.92; found C, 42.05; H, 3.60; N, 8.85.

6-(4-Bromo-2-iodoanilino)-2,3-dihydro-4(1H)-pyridinone (13e).

The reaction was carried out in *i*PrOH at 40 °C for 1h. Yield: 98%, as brown powder, m.p. 197-200 °C (dec.) (EtOAc/DCM). R_f 0.36 (EtOAc/MeOH, 9:1). ^1H NMR (600 MHz, DMSO- D_6) (δ , ppm): 8.24 (s, 1H, NH); 8.07 (s, 1H, Ar); 7.57 (d, $J = 7.8$ Hz, 1H, Ar); 7.19 (d, $J = 8.2$ Hz, 1H, Ar); 6.67 (s, 1H, NH); 4.18 (s, 1H, CH=); 3.32-3.30 (m, 2H, CH_2N); 2.10-2.08 (m, 2H, $\text{CH}_2\text{C}=\text{O}$). ^{13}C NMR (150 MHz, DMSO- D_6) (δ , ppm): 187.98 C; 160.07 C; 140.76 CH; 139.56 C; 131.99 CH; 128.90 CH; 118.80 C; 99.58 C; 82.41 CH; 39.66 CH_2 ; 35.43 CH_2 . $\text{C}_{11}\text{H}_{10}\text{BrIN}_2\text{O}$ (393.0): calcd. C, 33.62; H, 2.56; N, 7.13; found C, 33.59; H, 2.70; N, 7.16.

6-(Methylamino)-2,3-dihydro-4(1H)-pyridinone (13f).

The reaction was carried out in THF at 25 °C for 1h. Yield: 95%, as white solid, m.p. 218-219 °C (EtOAc/MeCN). R_f 0.24 (EtOAc/MeOH, 2:1). ^1H NMR (500 MHz, DMSO- D_6) (δ , ppm): 6.75 (br.s, 1H, NH); 6.72 (br.s, 1H, NH); 4.23 (s, 1H, CH=); 3.23 (t, $J = 7.1$ Hz, 2H, CH_2N); 2.61 (d, $J = 4.9$ Hz, 3H, CH_3N); 2.03 (t, $J = 7.2$ Hz, 2H, $\text{CH}_2\text{C}=\text{O}$). ^{13}C NMR (125 MHz, DMSO- D_6) (δ , ppm): 186.71; 163.52; 80.54; 40.29; 35.76; 28.19. HRMS Calcd for $\text{C}_6\text{H}_{10}\text{N}_2\text{O}$: 127.0866 (M+H). Found: 127.0863 (MH $^+$).

Ethyl (4-oxo-6-phenyl-1,4,5,6-tetrahydropyridin-2-yl)carbamate (18a).

The reaction was carried out in THF at 25 °C for 1h. Yield: 95%, as white powder, m.p. 188-189 °C (dec.). R_f 0.13 (EtOAc). ^1H NMR (400 MHz, DMSO- D_6) (δ , ppm): 10.28 (s, 1H, NH); 7.86 (s, 1H, NH); 7.40-7.31 (m, 5H, Ph); 4.81-4.77 (m, 2H, CHPh and CH= cycle); 4.14 (q, $J = 7.0$ Hz, 2H, OCH_2CH_3); 2.46-2.38 (m, 2H, $\text{CH}_2\text{C}=\text{O}$); 1.23 (t, $J = 7.0$ Hz, 2H, OCH_2CH_3). ^{13}C NMR (100 MHz, DMSO- D_6) (δ , ppm): 188.78; 157.14; 154.17; 141.39; 129.12 2C; 128.20; 126.80 2C; 85.85; 62.02; 55.26; 43.24; 14.61. $\text{C}_{14}\text{H}_{16}\text{N}_2\text{O}_3$ (260.3): calcd. C, 64.60; H, 6.20; N, 10.76; found C, 64.58; H, 6.27; N, 10.78.

Benzyl (4-oxo-6-phenyl-1,4,5,6-tetrahydropyridin-2-yl)carbamate (18b).

The reaction was carried out in THF at 40 °C for 40 min. Yield: 98%, as white powder, m.p. 82-83 °C. R_f 0.2 (EtOAc). ^1H NMR (400 MHz, CDCl_3) (δ , ppm): 10.11 (br.s, 1H, NH); 8.24 (s, 1H, NH); 7.40-7.28 (m, 10H, 2Ph); 5.17 (d, $J = 12.3$ Hz, 1H, $\text{CH}_A\text{H}_B\text{Ph}$); 5.13 (d, $J = 12.3$ Hz, 1H, $\text{CH}_A\text{H}_B\text{Ph}$); 5.05 (s, 1H, CH= cycle); 4.71 (dd, $J = 4.8, 14.1$ Hz, 1H, CHPh); 2.65 (dd, $J = 14.1, 16.4$ Hz, 1H, $\text{CH}_A\text{H}_B\text{C=O}$); 2.48 (dd, $J = 4.8, 16.4$ Hz, 1H, $\text{CH}_A\text{H}_B\text{C=O}$). ^{13}C NMR (100 MHz, CDCl_3) (δ , ppm): 190.26; 158.64; 154.30; 139.70; 135.01; 128.98 2C; 128.53 2C; 128.46; 128.36; 128.03 2C; 126.44 2C; 86.18; 67.63; 56.79; 42.95. $\text{C}_{19}\text{H}_{18}\text{N}_2\text{O}_3$ (322.4): calcd. C, 70.79; H, 5.63; N, 8.69; found C, 70.77; H, 5.49; N, 8.59.

***rac*- and (*S*)-6-(Methylamino)-2-phenyl-2,3-dihydro-4(1H)-pyridinone (18d) and ((*S*)-18d).**

The reaction was carried out in THF at 25 °C for 30 min. Yield: 96%, as white powder, **18d**: m.p. 205-206 °C; (**S**)-**18d**: m.p. 222-223 °C; $[\alpha]_D^{25} -32.2$ (C 0.5, MeOH). R_f 0.30 (EtOAc/MeOH, 4:1). ^1H NMR (400 MHz, $\text{DMSO-}D_6$) (δ , ppm): 7.36-7.30 (m, 4H, Ph); 7.26-7.23 (m, 1H, Ph); 6.71 (br.s, 1H, NH); 6.35 (br.s, 1H, NH); 4.57 (dd, $J = 7.2, 8.2$ Hz, 1H, CHPh); 4.26 (s, 1H, CH=); 2.63 (d, $J = 4.8$ Hz, 3H, NMe); 2.28 – 2.18 (m, 2H, $\text{CH}_2\text{C=O}$). ^{13}C NMR (100 MHz, $\text{DMSO-}D_6$) (δ , ppm): 185.36 br.; 162.97; 142.33; 128.40 2C; 127.36; 126.51 2C; 79.67 br.; 55.17; 43.77; 28.05. $\text{C}_{12}\text{H}_{14}\text{N}_2\text{O}$ (202.3): calcd. C, 71.26; H, 6.98; N, 13.85; found C, 71.37; H, 7.11; N, 13.74.

6-(2-Chlorophenylamino)-2-allyl-2,3-dihydro-2-phenylpyridin-4(1H)-one (22a).

The reaction was carried out in *i*PrOH at 45 °C for 4h. Yield: 89%, as white solid, m.p. 208-209 °C. R_f 0.23 (EtOAc/MeOH, 10:1). ^1H NMR (600 MHz, $\text{DMSO-}D_6$) (δ , ppm): 8.33 (s, 1H, NH); 7.59 (d, $J = 7.7$ Hz, 1H, Ar); 7.45-7.37 (m, 6H, Ph, Ar); 7.29 (t, $J = 6.8$ Hz, 1H, Ar); 7.25 (t, $J = 6.9$ Hz, 1H, Ar); 7.10 (s, 1H, NH); 5.56-5.49 (m, 1H, CH=, allyl); 5.18-5.14 (m, 2H, $\text{CH}_2 = \text{allyl}$); 4.18 (s, 1H, CH=); 2.72-2.63 (m, 4H, CH_2 allyl and $\text{CH}_2\text{C=O}$). ^{13}C NMR (100 MHz, $\text{DMSO-}D_6$) (δ , ppm): 187.51, 159.46, 144.33, 135.66, 133.16, 130.45, 128.62 2C, 128.27, 128.25, 127.28, 127.27, 126.93, 125.85 2C, 120.10, 82.46, 60.59, 47.06, 46.36. $\text{C}_{20}\text{H}_{19}\text{ClN}_2\text{O}$ (338.8): calcd. C, 70.90; H, 5.65; N, 8.27; found C, 70.74; H, 5.66; N, 8.19.

6-(*tert*-Butylamino)-2-phenyl-2-prop-2-en-1-yl-2,3-dihydropyridin-4(1H)-one (22c).

To a solution of enolester **27a** (0.284 g, 1.0 mmol) in THF (4 ml) was added *t*BuOK (0.168 g, 1.5 mmol) at -30 °C and the mixture was stirred for 1h at this temperature. Then AcOH (0.108 ml, 1.8 mmol) was added for neutralization, the mixture was filtered through the pad of Super Cel, evaporated and the solid residue was recrystallized from *n*- C_6H_{14} /Et₂O to give **22c** (0.204 g, 72%) as white powder, m.p. 121-122 °C (*n*- C_6H_{14} /Et₂O). R_f 0.12 (EtOAc/MeOH, 9:1). ^1H NMR (400 MHz, CDCl_3) (δ , ppm): 7.58 (br.s, 1H, NH); 7.31-7.23 (br.m, 6H, Ph and NH); 5.47 (br.s, 1H, CH= allyl); 4.97 (br. s, 2H, $\text{CH}_2 = \text{allyl}$); 4.80


(br.s, 1H, CH=); 2.74 (br.s, 2H, CH₂ cycle); 2.55 (br.s, 2H, CH₂ allyl); 1.27 (s, 9H, *t*Bu). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 184.69 br.; 161.73; 143.78; 132.23; 128.28 2C; 126.81; 125.27 2C; 119.58; 84.08; 59.74; 51.39; 46.85; 44.41 br.; 29.88 3C. C₁₈H₂₄N₂O (284.4): calcd. C, 76.02; H, 8.51; N, 9.85; found C, 75.98; H, 8.55; N, 9.82.


2-Phenyl-2-prop-2-en-1-yl-6-(prop-2-en-1-ylamino)-2,3-dihydropyridin-4(1H)-one (22d).

Yield: 85% as oil. R_f 0.25 (EtOAc/MeOH, 9:1). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 7.76 (br.s, 1H, NH); 7.66 (br.s, 1H, NH); 7.30-7.18 (m, 5H, Ph); 5.75-5.66 (m, 1H, CH= Nallyl); 5.50-5.40 (m, 1H, CH= allyl); 5.13 (d, *J* = 17.0 Hz, 1H, CH_AH_B= Nallyl); 5.07 (d, *J* = 10.2 Hz, 1H, CH_AH_B= Nallyl); 5.01-4.97 (m, 2H, CH₂= allyl); 4.60 (br.s, 1H, CH= cycle); 3.59 (br.s, 2H, CH₂N); 2.74 (s, 2H, CH₂C=O); 2.59-2.49 (m, 2H, CH₂ allyl). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 185.45; 162.82; 143.82; 132.24; 132.08; 128.26 2C; 126.93; 125.19 2C; 119.61; 116.58; 81.42; 59.84; 46.50; 44.38; 44.28. C₁₇H₂₀N₂O (268.4): calcd. C, 76.09; H, 7.51; N, 10.44; found C, 76.14; H, 7.48; N, 10.42.


2-Allyl-6-(methylamino)-2-phenyl-2,3-dihydropyridin-4(1H)-one (22e).


Yield: 48% as yellow solid, m.p. 83-84 °C. R_f 0.2 (EtOAc/MeOH, 5:1). ¹H NMR (400 MHz, CDCl₃) (δ, ppm): 7.28-7.15 (m, 7H, 2NH and Ph); 5.50-5.39 (m, 1H, CH= Nallyl); 5.01-4.96 (m, 2H, CH₂= allyl); 4.54 (br.s, 1H, CH= cycle); 2.75 (d, *J* = 16.6 Hz, 1H, CH_AH_BC=O); 2.70 (d, *J* = 16.6 Hz, 1H, CH_AH_BC=O); 2.63 (s, 3H, NMe); 2.56 (dd, *J* = 6.7, 14.0 Hz, 1H, CH_AH_B allyl); 2.51 (dd, *J* = 8.3, 14.0 Hz, 1H, CH_AH_B allyl). ¹³C NMR (100 MHz, CDCl₃) (δ, ppm): 186.27; 163.30; 143.84; 132.31; 128.33 2C; 126.96; 125.29 2C; 119.61; 80.85; 59.93; 46.52; 45.38; 28.53. C₁₅H₁₈N₂O (242.3): calcd. C, 74.35; H, 7.49; N, 11.56; found C, 74.27; H, 7.53; N, 11.48.







(S)-1-Phenyl-3-buten-1-amine hydrochloride (S)-7










1,1-Dimethyl-3-butenylamine (28)






1,1-Dimethyl-3-butenylamine (28)







N-(1-Allyl-1-phenyl-3-butenyl)-N-(4-methoxybenzyl)amine




158.5092
145.0714
133.9011
133.1501
129.2712
128.0317
126.7119
126.3547
118.0207
113.6970
77.3208
77.0000
76.6865
60.4196
55.2137
45.5381
41.8706





N-(1-Allyl-1-phenyl-3-butenyl)-N-(4-methoxybenzyl)amine







2-Methoxyethyl N-[(3-butenylamino)carbonyl]carbamate (11a)







2-Methoxyethyl N-[(3-butenylamino)carbonyl]carbamate (11a)







Benzyl N-[(3-butenylamino)carbonyl]carbamate (11b)










4-Methylphenylsulfonyl-N-(3-butenylamino)carbamate (11c)







4-Methylphenylsulfonyl-N-(3-butenylamino)carbamate (11c)









N-(3-Butenyl)-N'-(2-iodophenyl)urea (11d)















N-(3-butenyl)-N'-(tert-butyl)urea (11g)







N-(3-butenyl)-N'-(tert-butyl)urea (11g)







Ethyl N-[(1-phenyl-3-butenyl)amino]carbonylcarbamate (16a)










Benzyl N-[(1-phenyl-3-butenyl)amino]carbonylcarbamate (16b)










N-(tert-Butyl)-N'-(1-phenyl-3-butenyl)urea (16c)










N-methyl-N'-(1-phenyl-3-butenyl)urea (16d)









Benzyl N-[[[(1-phenyl-3-butynyl)amino]carbonyl]carbamate (21).




S49





Benzyl N-[[1-(1-phenyl-3-butynyl)amino]carbonyl]carbamate (21).







N-(1-Allyl-1-phenyl-3-butenyl)-N'-(2-chlorophenyl)urea (20a)








2-Methoxyethyl N-[[[(1-allyl-1-phenyl-3-butenyl)amino]carbonyl]carbamate (20b)



S53



154.4406
151.6991

143.5693

132.8439

128.0973

126.5442

125.4068

119.0050

77.3208
77.0000
76.6865

69.9493


64.8892


60.7332

58.9030


42.7018

2-Methoxyethyl N-[(1-allyl-1-phenyl-3-butenyl)amino]carbonylcarbamate (20b)







N-Allyl-N'-(1-allyl-1-phenyl-3-butenyl)urea (20d)





S55







N-(1-Allyl-1-phenyl-3-butenyl)-N'-(tert-butyl)urea (20c)







N-(1-Allyl-1-phenyl-3-butenyl)-N'-methylurea (20e)



— 158.0426

— 144.5610

— 133.2522

— 128.2650

— 126.7703

— 125.8443


— 118.9030

77.3135
77.0000
76.6792


— 59.1291


— 43.0081

— 26.8725





N-(1-Allyl-1-phenyl-3-butenyl)-N'-methylurea (20e)







N-(1-Allyl-1-phenyl-3-butenyl)-N'-(tert-butyl)-N-(4-methoxybenzyl)urea (24a)







N-(1-Allyl-1-phenyl-3-butenyl)-N'-(allyl)-N-(4-methoxybenzyl)urea (24b)



158.9062
158.4761

145.5997

135.1658
133.4013
130.9296
128.8662
128.8370
127.3058
126.1976

119.3365

114.6701
113.9555


77.4481
77.1346
76.8137

65.3956


55.2680


48.3778

43.3103
40.8021





N-(1-Allyl-1-phenyl-3-butenyl)-N'-(allyl)-N-(4-methoxybenzyl)urea (24b)







N-(1-adamantyl)-N'-(3-butenyl)urea (36a)






N-(1-adamantyl)-N'-(3-butenyl)urea (36a)





N-(1-adamantyl)-N'-(2-methylpent-4-en-2-yl)urea (36b)



156.7884

134.6667

117.9697


77.3135
77.0000
76.6792

52.1586
50.5472


45.2611
42.4029


36.3657

29.4754
27.4922




N-(1-adamantyl)-N'-(2-methylpent-4-en-2-yl)urea (36b)






2-Methoxyethyl N-[6-(bromomethyl)-1,3-oxazinan-2-ylidene]carbamate (12a)




163.8882
161.7787




77.4265
77.0000
76.5773
74.8981
70.2680
63.7682
58.5555


37.3389
32.0081
24.0576

2-Methoxyethyl N-[6-(bromomethyl)-1,3-oxazinan-2-ylidene]carbamate (12a)





Benzyl N-[6-(bromomethyl)-1,3-oxazinan-2-ylidene]carbamate (12b)




164.0870
162.0309


136.8030
128.2066
127.6015
127.4994


77.3208
77.0000
76.6865
75.2209
66.7266

37.5396
31.7576
24.2986




Benzyl N-[6-(bromomethyl)-1,3-oxazinan-2-ylidene]carbamate (12b)






N-[6-(Bromomethyl)-1,3-oxazinan-2-yliden]-4-methylbenzenesulfonamide (12c)



— 156.1501

— 141.8301
— 141.5457

— 129.4130
— 126.8611





— 77.2731

40.5251
40.3136
40.1095
39.8980
39.6866
39.4824
39.2710
37.6523
34.3712


— 24.2072
— 21.4073


N-[6-(Bromomethyl)-1,3-oxazinan-2-ylidene]-4-methylbenzenesulfonamide (12c)





N-[6-(Iodomethyl)-1,3-oxazinan-2-yliden]-N-(2-iodophenyl)amine (12d)





N-[6-(Iodomethyl)-1,3-oxazinan-2-yliden]-N-(2-iodophenyl)amine (12d)

— 149.1195
— 144.7560
— 138.5909
— 128.6779
— 123.5770
— 122.4139


— 92.8728


77.3193
77.0000
76.6807
75.2211

— 39.2640


— 27.0021


— 6.1880







N-(4-Bromo-2-iodophenyl)-N-[6-(bromomethyl)-1,3-oxazin-2-ylidene]amine (12e)








N-[6-(bromomethyl)-1,3-oxazinan-2-ylidene]-N-methylamine (12f)



— 152.7345




N-[6-(bromomethyl)-1,3-oxazinan-2-ylidene]-*N*-methylamine (12f)


77.3135
77.0000
76.6792
74.6595

— 40.5946


— 33.5659

— 27.9807
— 26.1215






N-[6-(Bromomethyl)-1,3-oxazinan-2-ylidene]-N-(tert-butyl)amine (12g)



150.8239



N-[6-(Bromomethyl)-1,3-oxazinan-2-yliden]-N-(tert-butyl)amine (12g)

77.0000
74.2623


50.3727


40.9905

33.8701


29.4417


26.3727






Ethyl N-[6-(bromomethyl)-4-phenyl-1,3-oxazinan-2-ylidene]carbamate (17a)





Benzyl trans-N-[6-(bromomethyl)-4-phenyl-1,3-oxazinan-2-ylidene]carbamate (trans-17b)




163.9111
162.0482

140.0677
136.6842
129.1291
128.3967
128.2853
127.7200
127.6723
125.6740


77.3184
77.0000
76.6816
71.7775
66.9690


50.9354

32.3861
31.6218




Benzyl trans-N-[6-(bromomethyl)-4-phenyl-1,3-oxazinan-2-ylidene]carbamate (trans-17b)





Benzyl cis-N-[6-(bromomethyl)-4-phenyl-1,3-oxazinan-2-ylidene]carbamate (cis-17b)




164.0942
162.0164

138.9292
136.6524
129.2247
128.8346
128.2216
127.6325
127.5210
125.8731


77.3184
77.0000
76.6816
75.2884
66.7541


53.9367

34.5993
31.9960





Benzyl cis-N-[6-(bromomethyl)-4-phenyl-1,3-oxazinan-2-ylidene]carbamate (cis-17b)










cis-N-[6-(Bromomethyl)-4-phenyl-1,3-oxazinan-2-ylidene]-N-(tert-butyl)amine (*cis*-17c)







cis-N-[6-(Bromomethyl)-4-phenyl-1,3-oxazinan-2-ylidene]-*N*-(tert-butyl)amine (*cis*-17c)







N-[6-(bromomethyl)-4-phenyl-1,3-oxazinan-2-ylidene]-N-methylamine (17d)







N-[4-Allyl-6-(bromomethyl)-4-phenyl-1,3-oxazinan-2-ylidene]-2-chloroaniline (21a)










2-Methoxyethyl N-[4-allyl-6-(bromomethyl)-4-phenyl-1,3-oxazinan-2-ylidene]carbamate (21b)










N-[4-Allyl-6-(bromomethyl)-4-phenyl-1,3-oxazinan-2-ylidene]-N-(tert-butyl)amine (21c)










N-[4-Allyl-6-(bromomethyl)-4-phenyl-1,3-oxazinan-2-yliden]-2-propen-1-amine (21d).









N-[4-Allyl-6-(bromomethyl)-4-phenyl-1,3-oxazinan-2-ylidene]methanamine (21e)



151.3054
147.7546
134.9875
128.0681
126.2526
126.0849
117.4083
71.1961
58.1302
49.1036
37.7000
34.5575
28.4036





N-[4-Allyl-6-(bromomethyl)-4-phenyl-1,3-oxazinan-2-ylidene]methanamine (21e)



S100



N-[4-Allyl-6-(bromomethyl)-3-(4-methoxybenzyl)-4-phenyl-1,3-oxazinan-2-yliden]-2-methyl-2-propanamine (25a)





S101


157.8492
 147.2142
 146.3270
 133.4531
 132.4898
 129.4398
 128.6745
 127.2009
 126.3441
 119.5283
 112.8268
 77.4227
 77.0000
 76.5735
 70.2489
 63.1285
 55.1437
 51.7016
 48.7011
 43.7206
 40.9638
 33.8777
 30.6525

N-[4-Allyl-6-(bromomethyl)-3-(4-methoxybenzyl)-4-phenyl-1,3-oxazinan-2-ylidene]-2-methyl-2-propanamine (25a)




N-[4-Allyl-6-(bromomethyl)-3-(4-methoxybenzyl)-4-phenyl-1,3-oxazinan-2-yliden]-2-propen-1-amine (25b)







S104




2-Methyl-N-{4-phenyl-6-[(phenylselanyl)methyl]-1,3-oxazinan-2-yliden}-2-propanamine (37a)






N-{6-[(Phenylselanyl)methyl]-1,3-oxazinan-2-yliden}-1-adamantanamine (37b)



151.2762

132.8731
129.7670
129.1180
127.1859





77.3135
77.0000
76.6792
74.6668

50.7733


42.4685
41.4113
36.3438
32.3191
29.5192
27.7328


N-[6-[(Phenylselanyl)methyl]-1,3-oxazinan-2-ylidene]-1-adamantanamine (37b)







N-{4,4-Dimethyl-6-[(phenylselanyl)methyl]-1,3-oxazinan-2-yliden}-1-adamantanamine (37c)








N-(Adamantan-1-yl)-6-methylene-1,3-oxazinan-2-imine (38a)



S110

154.0870

148.7680



89.4316

77.3208
77.0000
76.6828

51.1160


42.2352
41.2946

36.3438


29.4937

26.1689


N-(Adamantan-1-yl)-6-methylene-1,3-oxazinan-2-imine (38a)



S111




N-(Adamantan-1-yl)-4,4-dimethyl-6-methylene-1,3-oxazinan-2-imine (38b)



S112

— 153.1136
— 147.9295



— 90.4743


— 77.3208
— 77.0000
— 76.6865


— 51.1160
— 49.4608

— 42.4904
— 39.0052
— 36.4095


— 29.8036
— 29.5629

N-(Adamantan-1-yl)-4,4-dimethyl-6-methylene-1,3-oxazinan-2-imine (38b)






N-(tert-Butyl)-6-methylene-1,3-oxazinan-2-imine (38c)



S114

— 153.0262
— 148.4764
— 144.4735

— 128.2431
— 126.6901
— 126.2672




— 90.2847


— 77.3135
— 77.0000
— 76.6792

— 54.8054
— 50.7587


— 35.0314
— 29.2348

N-(tert-Butyl)-6-methylene-1,3-oxazinan-2-imine (38c)






N-[4-Allyl-3-(4-methoxybenzyl)-6-methylene-4-phenyl-1,3-oxazinan-2-yliden]-2-methyl-2-propanamine (26a)




S116




N-[4-Allyl-3-(4-methoxybenzyl)-6-methylene-4-phenyl-1,3-oxazinan-2-ylidene]-2-methyl-2-propanamine (26a)






N-[4-Allyl-3-(4-methoxybenzyl)-6-methylene-4-phenyl-1,3-oxazinan-2-yliden]-2-propen-1-amine (26b)




S118






N-[4-Allyl-3-(4-methoxybenzyl)-6-methylene-4-phenyl-1,3-oxazinan-2-ylidene]-2-propen-1-amine (26b)






N-(4-Allyl-6-methylene-4-phenyl-1,3-oxazinan-2-yliden)-2-methyl-2-propanamine (27a)







S121




N-(4-Allyl-6-methylene-4-phenyl-1,3-oxazinan-2-yliden)-2-propen-1-amine (27b)




S122




S123




Benzyl N-(6-methylene-1,3-oxazinan-2-ylidene)carbamate (14)




S124




S125





4-Methyl-N-(6-methylene-1,3-oxazinan-2-yliden)benzenesulfonamide (15)







4-Methyl-N-(6-methylene-1,3-oxazinan-2-ylidene)benzenesulfonamide (15)







Benzyl N-(6-methylene-4-phenyl-1,3-oxazinan-2-ylidene)carbamate (19)







Benzyl N-(6-methylene-4-phenyl-1,3-oxazinan-2-ylidene)carbamate (19)






2-Methoxyethyl N-(4-oxo-1,4,5,6-tetrahydro-2-pyridinyl)carbamate (13a)







2-Methoxyethyl N-(4-oxo-1,4,5,6-tetrahydro-2-pyridinyl)carbamate (13a)

86.0014
77.4227
77.0000
76.5735
70.1080
64.4193
58.6316
40.3927
34.5630





Benzyl N-(4-oxo-1,4,5,6-tetrahydro-2-pyridinyl)carbamate (13b)



— 190.7287

— 158.6145

— 154.2509

— 135.0448

— 128.5602

— 128.5107

— 128.1604

— 86.1004

— 77.4227


— 77.0000

— 76.5735


— 67.6635


— 40.2556

— 34.2508




Benzyl N-(4-oxo-1,4,5,6-tetrahydro-2-pyridinyl)carbamate (13b)






4-Methyl-N-(4-oxo-2-piperidinydene)benzenesulfonamide (13c)



— 201.4366



— 162.4784

— 143.3193

— 138.7417

— 129.4544

— 126.3934

77.3131
77.2018
77.0000
76.6800


— 47.1344


— 38.9393

— 37.5966


— 21.5125


4-Methyl-N-(4-oxo-2-piperidinylidene)benzenesulfonamide (13c)






6-(2-Iodoanilino)-2,3-dihydro-4(1H)-pyridinone (13d)







S137





6-(4-Bromo-2-iodoanilino)-2,3-dihydro-4(1H)-pyridinone (13e)






6-(4-Bromo-2-iodoanilino)-2,3-dihydro-4(1H)-pyridinone (13e)







S140




6-(Methylamino)-2,3-dihydro-4(1H)-pyridinone (13f)






S142



Ethyl (4-oxo-6-phenyl-1,4,5,6-tetrahydropyridin-2-yl)carbamate (18a)




— 188.7859

— 157.1417
— 154.1742

— 141.3926

— 129.1214
— 128.2027
— 126.8027



— 85.8549


— 62.0270


— 55.2680

— 43.2447
— 39.9490


— 14.6119

Ethyl (4-oxo-6-phenyl-1,4,5,6-tetrahydropyridin-2-yl)carbamate (18a)







Benzyl (4-oxo-6-phenyl-1,4,5,6-tetrahydropyridin-2-yl)carbamate (18b)




S145




Benzyl (4-oxo-6-phenyl-1,4,5,6-tetrahydropyridin-2-yl)carbamate (18b)





6-(Methylamino)-2-phenyl-2,3-dihydro-4(1H)-pyridinone (18d)




— 185.3695

— 162.9792

— 142.3353

— 128.4011
— 127.3716
— 126.5168



— 79.6681


— 55.1730


— 43.7664

— 39.5200


— 28.0491


6-(Methylamino)-2-phenyl-2,3-dihydro-4(1H)-pyridinone (18d)






6-(2-Chlorophenylamino)-2-allyl-2,3-dihydro-2-phenylpyridin-4(1H)-one (22a)







S150




6-(tert-Butylamino)-2-phenyl-2-prop-2-en-1-yl-2,3-dihydropyridin-4(1H)-one (22c)




S151




S152




2-Phenyl-2-prop-2-en-1-yl-6-(prop-2-en-1-ylamino)-2,3-dihydropyridin-4(1H)-one (22d)




S153




2-Phenyl-2-prop-2-en-1-yl-6-(prop-2-en-1-ylamino)-2,3-dihydropyridin-4(1H)-one (22d)




2-Allyl-6-(methylamino)-2-phenyl-2,3-dihydropyridin-4(1H)-one (22e)




S155




S156




N-(1-Adamantyl)carbodiimide (32a)



S157





N-(1-Adamantyl)carbodiimide (32a)




Enantiomeric analysis of urea (S)-16d.

Column Chiralcel OD-H, eluent *n*-C₆H₁₄/*iso*-PrOH = 9/1, flow rate 1.0 ml/min, UV 219 nm.
rac-16d.




(S)-16d, first crystallization, ee 94.7%.



S160

(S)-16d, second crystallization, ee 98.6%.





S161


Enantiomeric analysis of 2,3-dihydro-4-pyridinone (*S*)-18d.

Column Chiralcel OD-H, eluent *n*-C₆H₁₄/*iso*-PrOH/Et₂NH/Et₃N=80/20/0.1/0.1, flow rate 1.0 ml/min, UV 219 nm.

rac-18d.



(S)-18d, ee 99%.



ⁱ C. A. Grob, V. Krasnobajew, *Helv. Chim. Acta*, 1964, **47**, 2145.

ⁱⁱ S. Laschat, H. Kunz, *J. Org. Chem.*, 1991, **56**, 5883.

ⁱⁱⁱ S. Magnelinckx, Y. Nural, H. A. Dondas, B. Denolf, R. Sillanpaa, N. De Kimpe, *Tetrahedron*, 2010, **66**, 4115.